Stevia Corp., a farm management company focused on the economic development of alternative sweetener stevia, today announced it has entered into an Equity Purchase Agreement of up to $20 million of the company’s registered common stock by institutional investor Southridge Partners II, LP. Stevia Corp. will allocate this funding to accelerate its commercial development of stevia and related markets.
Stevia Corp. president George Blankenbaker said the funding is a significant achievement that reflects Southridge’s support of Stevia Corp.’s future plans and market opportunity.
“This is an important milestone for Stevia Corp. to have accomplished. We have attracted and won the confidence of a forward-thinking institutional investor which says a lot about their conviction regarding our vision, management approach, and overall market demand,” Blankenbaker stated in the press release. “Having a flexible and low cost funding instrument in place allows us to efficiently accelerate our commercialization and acquisition strategies.”
Per the agreement, Stevia Corp. may sell to Southridge up to $20 million of its common stock from time to time over a 36-month period.
The company is not obligated, but does have the right to sell stock to Southridge depending on certain conditions as set forth in the equity agreement.
For more information visit www.steviacorp.us
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, January 31, 2012
Monday, January 30, 2012
Hyperdynamics Corp. (HDY) Issues Update on Financial and Operational Activity
Hyperdynamics Corp. said plans to engage in a direct offering of common stock to raise capital to continue its oil and gas exploration and development activities in Africa and other areas. The company will issue ten million shares of common stock at a price of $3.00 per share to a group of institutional investors.
Hyperdynamics will also issue associated warrants in the common stock offering. Each warrant will allow the holder to purchase one share of Hyperdynamics Corp. common stock at an exercise price of $3.50 per share. The warrants expire in 14 months and can’t be exercised until six months after the offering.
The offering is being conducted by a subsidiary of Rodman & Renshaw Capital Group, Inc., and is expected to close in early February 2012.
Hyperdynamics also announced that the company has restarted drilling on an exploration well located offshore West Africa. The Sabu-1 well is on a concession granted by the Republic of Guinea and is being drilled to a subsea depth of 3,600 meters. The well is targeting sandstone reservoirs in the upper Cretaceous zone.
For more information on the company, go to www.hyperdynamics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Hyperdynamics will also issue associated warrants in the common stock offering. Each warrant will allow the holder to purchase one share of Hyperdynamics Corp. common stock at an exercise price of $3.50 per share. The warrants expire in 14 months and can’t be exercised until six months after the offering.
The offering is being conducted by a subsidiary of Rodman & Renshaw Capital Group, Inc., and is expected to close in early February 2012.
Hyperdynamics also announced that the company has restarted drilling on an exploration well located offshore West Africa. The Sabu-1 well is on a concession granted by the Republic of Guinea and is being drilled to a subsea depth of 3,600 meters. The well is targeting sandstone reservoirs in the upper Cretaceous zone.
For more information on the company, go to www.hyperdynamics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SoundBite Communications (SDBT) Announces Record Preliminary Fourth Quarter Financial Results
SoundBite Communications, Inc., a leading cloud communications provider and supplier of mobile marketing and contact center solutions, announced today that its preliminary unaudited fourth quarter revenue for 2011, computed according to U.S. generally accepted accounting principles (GAAP), is projected to be the highest in the company’s history – exceeding $11 million. This is a significant increase in comparison with same-quarter revenue from the previous year, which was $10.1 million. SoundBite’s GAAP operating income for the fourth quarter of 2011 has been calculated to be at least $200,000, contrasted with $50,000 in 2010.
SoundBite additionally forecasts non-GAAP operating income of at least $800,000, exceeding its previously guided range of $100,000 to $400,000. The following estimated amounts were excluded from the company’s calculations of preliminary non-GAAP operating income: stock-based compensation of $300,000 and amortization of intangibles of $300,000 associated with the company’s acquisition of SmartReply.
For the full 2011 year, SoundBite anticipates revenues of at least $41.5 million, which is a growth of 5 percent over the company’s 2010 revenues.
These fourth quarter results are based on preliminary analyses of SoundBite’s revenue and GAAP operating income; the company will release official fourth-quarter and full-year financial results on Wednesday, Feb. 22 after market close, and then discuss them at 5 p.m. EST during the scheduled conference call.
SoundBite Communications assists organizations in building lasting, gainful consumer relations through forward-looking communications. The company serves two global markets: the hosted contact center and mobile marketing. SoundBite’s solutions employ two platforms: SoundBite Engage, which is an interactive multi-channel communications platform providing customers with integrated SMS, dialer, voice messaging, Web communications and e-mail; and SoundBite Insight, which is a preference management platform that facilitates personalized, intelligent communication. Each year, SoundBite powers nearly 2 billion customers.
For further information about the company, visit www.SoundBite.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SoundBite additionally forecasts non-GAAP operating income of at least $800,000, exceeding its previously guided range of $100,000 to $400,000. The following estimated amounts were excluded from the company’s calculations of preliminary non-GAAP operating income: stock-based compensation of $300,000 and amortization of intangibles of $300,000 associated with the company’s acquisition of SmartReply.
For the full 2011 year, SoundBite anticipates revenues of at least $41.5 million, which is a growth of 5 percent over the company’s 2010 revenues.
These fourth quarter results are based on preliminary analyses of SoundBite’s revenue and GAAP operating income; the company will release official fourth-quarter and full-year financial results on Wednesday, Feb. 22 after market close, and then discuss them at 5 p.m. EST during the scheduled conference call.
SoundBite Communications assists organizations in building lasting, gainful consumer relations through forward-looking communications. The company serves two global markets: the hosted contact center and mobile marketing. SoundBite’s solutions employ two platforms: SoundBite Engage, which is an interactive multi-channel communications platform providing customers with integrated SMS, dialer, voice messaging, Web communications and e-mail; and SoundBite Insight, which is a preference management platform that facilitates personalized, intelligent communication. Each year, SoundBite powers nearly 2 billion customers.
For further information about the company, visit www.SoundBite.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
XcelMobility Inc. (XCLL) Announces Contract with ZTE to Introduce Wireless Products to Chinese Marketplace
XcelMobility Inc., a developer of high speed web browsing solutions and related performance enhancing products for mobile devices, today announced a contract with ZTE Corp. of China to install the Mach 5 Xcelerator on an initial run of 1 million wireless devices for China Unicom, third largest mobile provider in the world. The agreement is for ZTE to help introduce Xcel products to the Chinese market; if successful, projections are for installation of up to 30 million units per year.
“This is an extraordinary opportunity to really fast-track the introduction of our products to an ever wider audience through the auspices of an exceptional global partner like ZTE. The culture at ZTE is based on innovation that responds to market drivers and this represents a tremendous opportunity for us to work with a partner with a similar outlook regarding the future of mobility. We anticipate very competitive consumer pricing and the public can expect product availability shortly,” said Ryan Ge, CEO, XcelMobility Inc in a press statement.
XcelMobility creates applications and solutions that deliver high speed internet access to cellular and smart phones, tablets, and mobile computers. Its flagship product, the Mach 5 Xcelerator, has been independently tested by some of the world’s largest cellular carriers, including Nokia, Sony, China Unicom, NTT Docomo, and Ericsson. All have found that the Mach 5 software, either through a download or embedded by cellular manufacturers, provides 5 to 10 times faster speeds than standard mobile web browsers used for browsing, downloads, videos and email. Xcel Mobility uses patented software and algorithms to compress voice and data transmissions both on mobile devices and on servers strategically located throughout China, Japan, and Hong Kong. Presently, there are over 1.3 million users and the number is growing.
Xcel believes that the Asia marketplace is the best option for focusing commercialization efforts prior to a product roll out on a global scale. ZTE Corp., China’s largest publicly listed telecom equipment company, brings the industry’s most comprehensive product range of end-to-end solutions and expertise in the telecommunications sector to over 500 operators in more than 140 countries around the globe.
For more information on XcelMobility Inc, please visit www.xcelmobility.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“This is an extraordinary opportunity to really fast-track the introduction of our products to an ever wider audience through the auspices of an exceptional global partner like ZTE. The culture at ZTE is based on innovation that responds to market drivers and this represents a tremendous opportunity for us to work with a partner with a similar outlook regarding the future of mobility. We anticipate very competitive consumer pricing and the public can expect product availability shortly,” said Ryan Ge, CEO, XcelMobility Inc in a press statement.
XcelMobility creates applications and solutions that deliver high speed internet access to cellular and smart phones, tablets, and mobile computers. Its flagship product, the Mach 5 Xcelerator, has been independently tested by some of the world’s largest cellular carriers, including Nokia, Sony, China Unicom, NTT Docomo, and Ericsson. All have found that the Mach 5 software, either through a download or embedded by cellular manufacturers, provides 5 to 10 times faster speeds than standard mobile web browsers used for browsing, downloads, videos and email. Xcel Mobility uses patented software and algorithms to compress voice and data transmissions both on mobile devices and on servers strategically located throughout China, Japan, and Hong Kong. Presently, there are over 1.3 million users and the number is growing.
Xcel believes that the Asia marketplace is the best option for focusing commercialization efforts prior to a product roll out on a global scale. ZTE Corp., China’s largest publicly listed telecom equipment company, brings the industry’s most comprehensive product range of end-to-end solutions and expertise in the telecommunications sector to over 500 operators in more than 140 countries around the globe.
For more information on XcelMobility Inc, please visit www.xcelmobility.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
L&L Energy (LLEN) to Acquire Majority Stake in Weishe Coal Mine
Through its subsidiaries, L&L Energy operates coal mines, coking, and coal washing facilities in the Yunnan and Guizhou Provinces of China. Using expertise gained in the U.S., the company is using improved mining standards in China to gain a competitive advantage.
L&L today announced that it entered into an agreement to acquire a 51% controlling interest in the Weishe coal mine located in the Guizhou Province of China from the Chinese miner Union Energy. This mine produces high quality, low sulfur anthracite coal. The company will acquire the interest for a purchase price of approximately $16.2 million to be paid in the form of three million LLEN shares at $5.395 a share.
The Weishe mine has reserves of 19 million tons of coal. It is expected to be expanded to 450,000 tons of annual production of coal over the next five years. The Weishe mine is anticipated to produce about 124,000 tons of coal in the current fiscal year, sold at an average price of $158 a ton.
This acquisition is the first such purchase made to upgrade the company’s mining portfolio for better safety and mechanization. There is a strong possibility that L&L may add to its portfolio through other joint ventures with Union Energy, which has two other newly constructed coal mines in the same area that will begin operations later this year.
For further information about L&L Energy and its coal business in China, please visit the company’s website at www.llenergyinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
L&L today announced that it entered into an agreement to acquire a 51% controlling interest in the Weishe coal mine located in the Guizhou Province of China from the Chinese miner Union Energy. This mine produces high quality, low sulfur anthracite coal. The company will acquire the interest for a purchase price of approximately $16.2 million to be paid in the form of three million LLEN shares at $5.395 a share.
The Weishe mine has reserves of 19 million tons of coal. It is expected to be expanded to 450,000 tons of annual production of coal over the next five years. The Weishe mine is anticipated to produce about 124,000 tons of coal in the current fiscal year, sold at an average price of $158 a ton.
This acquisition is the first such purchase made to upgrade the company’s mining portfolio for better safety and mechanization. There is a strong possibility that L&L may add to its portfolio through other joint ventures with Union Energy, which has two other newly constructed coal mines in the same area that will begin operations later this year.
For further information about L&L Energy and its coal business in China, please visit the company’s website at www.llenergyinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cytori Therapeutics (CYTX) Gets Green Light from FDA to Initiate Cardiac Cell Therapy Trial
Cytori Therapeutics today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to begin the ATHENA trial to investigate the use of the company’s Celution® System.
Cytori develops medical technologies to realize the potential of adult regenerative cells from fatty (adipose) tissue. The Celution® System is an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) to treat chronic myocardial ischemia (CMI), a form of coronary heart disease. The company sells its Celution® System family of medical devices in the European and Asian cosmetic and reconstructive surgery markets. Per today’s news, the device is available in the U.S. as an investigational advice.
“Following our pre-IDE meeting with the FDA, we received constructive guidance and implemented the Agency’s recommendations, ultimately resulting in rapid approval to initiate the ATHENA trial,” Christopher J. Calhoun, CEO for Cytori stated in the press release. “We look forward to working with the FDA on further defining our clinical strategy in the U.S.”
The ATHENA trial will enroll up to 45 patients to evaluate several clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12 months.
For more information visit www.cytori.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cytori develops medical technologies to realize the potential of adult regenerative cells from fatty (adipose) tissue. The Celution® System is an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) to treat chronic myocardial ischemia (CMI), a form of coronary heart disease. The company sells its Celution® System family of medical devices in the European and Asian cosmetic and reconstructive surgery markets. Per today’s news, the device is available in the U.S. as an investigational advice.
“Following our pre-IDE meeting with the FDA, we received constructive guidance and implemented the Agency’s recommendations, ultimately resulting in rapid approval to initiate the ATHENA trial,” Christopher J. Calhoun, CEO for Cytori stated in the press release. “We look forward to working with the FDA on further defining our clinical strategy in the U.S.”
The ATHENA trial will enroll up to 45 patients to evaluate several clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12 months.
For more information visit www.cytori.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Case for FluoroPharma Medical, Inc. (FPMI)
When FluoroPharma CEO, Thijs Spoor, recently gave a presentation summarizing the rising importance in medical diagnostics of PET technology, and the associated radiopharmaceuticals such as those developed by FluoroPharma, it brought into focus a major gap between the promise of PET and the current availability of chemical agents needed to make the promise a reality.
PET (Positron Emission Tomography) is a branch of nuclear medicine imaging that uses mildly radioactive tracer chemicals to highlight extremely subtle biological processes actively taking place at the cellular and even molecular level within the human body. As such, it represents functional scanning versus simply structural scanning. It doesn’t just show how the body looks, but what the body is doing at the most detailed level. The result is the highest contrast resolution available for internal imaging.
However, none of it works without the availability of suitable tracer chemicals which can insinuate themselves into otherwise imperceptible biological processes, making them visible to the advanced PET hardware and software. For a given targeted process, the market requires an appropriate and safe tracer chemical. Nuclear cardiologists, for example, are very anxious for new tracer agents that can be used to better identify and track processes related to heart disease. In particular, cardiology clinicians are looking for a vulnerable plaque imaging agent, a better profusion agent, and a viability agent, all of which are now part of the FluoroPharm portfolio:
• BFET – For myocardial perfusion imaging (measuring cardiovascular blood flow)
• CardioPET – For cardiac viability assessment (detecting regions of metabolic insufficiency)
• VasoPET – For inflamed atherosclerotic plaque imaging (detecting inflamed plaque)
These targeting agents can make a big difference in the treatment of heart disease, still the number one killer in the country. In the case of FluoroPharma’s VasoPET product, used for detecting inflamed plaque, which is the most unstable and dangerous type of plaque, early detection is critical, since the first symptom of such a problem is often sudden death.
Because there are still a very limited number of such tracer agents, the thousands of expensive PET scanners currently in hospitals around the country and the world are significantly under-utilized, creating a cost effectiveness issue that only more and better agents can address. In addition, the production of such agents by cyclotron operators requires a high level of fixed costs which, when spread over a handful of agents, increases the per unit cost of agents. So there is also a strong economic need for new agents to be developed.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
PET (Positron Emission Tomography) is a branch of nuclear medicine imaging that uses mildly radioactive tracer chemicals to highlight extremely subtle biological processes actively taking place at the cellular and even molecular level within the human body. As such, it represents functional scanning versus simply structural scanning. It doesn’t just show how the body looks, but what the body is doing at the most detailed level. The result is the highest contrast resolution available for internal imaging.
However, none of it works without the availability of suitable tracer chemicals which can insinuate themselves into otherwise imperceptible biological processes, making them visible to the advanced PET hardware and software. For a given targeted process, the market requires an appropriate and safe tracer chemical. Nuclear cardiologists, for example, are very anxious for new tracer agents that can be used to better identify and track processes related to heart disease. In particular, cardiology clinicians are looking for a vulnerable plaque imaging agent, a better profusion agent, and a viability agent, all of which are now part of the FluoroPharm portfolio:
• BFET – For myocardial perfusion imaging (measuring cardiovascular blood flow)
• CardioPET – For cardiac viability assessment (detecting regions of metabolic insufficiency)
• VasoPET – For inflamed atherosclerotic plaque imaging (detecting inflamed plaque)
These targeting agents can make a big difference in the treatment of heart disease, still the number one killer in the country. In the case of FluoroPharma’s VasoPET product, used for detecting inflamed plaque, which is the most unstable and dangerous type of plaque, early detection is critical, since the first symptom of such a problem is often sudden death.
Because there are still a very limited number of such tracer agents, the thousands of expensive PET scanners currently in hospitals around the country and the world are significantly under-utilized, creating a cost effectiveness issue that only more and better agents can address. In addition, the production of such agents by cyclotron operators requires a high level of fixed costs which, when spread over a handful of agents, increases the per unit cost of agents. So there is also a strong economic need for new agents to be developed.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
AdCare Health Systems, Inc. (ADK) Gets Green Light from Stonegate
According to a recent investment analysis report by Stonegate Securities, AdCare, an Ohio-based developer, owner, and operator of skilled nursing and assisted living communities, “holds significant potential for investors”. It bases its conclusion on the following:
• AdCare is executing an aggressive acquisition strategy – The company has begun buying skilled nursing facilities from independent operators, with the acquisition target calling for optimization potential and a reasonable price. According to a recent press release, 54 facilities have been put under contract since the campaign began. AdCare has been careful to avoid states with unhealthy economies, and has focused on the Southeast, Southwest, and Midwest.
• AdCare is improving the metrics associated with the acquired facilities – Once an appropriate property is acquired, AdCare increases the acuity level of the services it offers, increasing the Medicare census and the resulting reimbursement rates. In addition, AdCare identifies and implements various operational efficiencies, improving the bottom line. As a result, the company’s Medicare census has increased by 37.5% at acquired facilities. AdCare has also been able to offset recent cuts in Medicare reimbursements.
• AdCare revenues are increasing at record rates – Third quarter 2011 revenues increased a record 208% over the prior year, to $40.9 million, due to the company’s acquisition strategy and operation optimization results. Given the company’s success to date, and the announced acquisitions yet to close, management guidance points to annual recurring revenue of over $300 million, a 460% increase over 2010 levels. And this doesn’t include acquisitions not yet announced.
• AdCare has unique growth opportunities due to a fragmented but growing industry – The overall value of the long-term care market grew from $186 billion in 2005 to $258 billion in 2010, and is expected to continue to grow at over 6% annually. The skilled nursing care market, AdCare’s acquisition focus, is the biggest market segment. The long-term care market is extremely fragmented, with roughly 80% of nursing homes being privately owned single facilities, providing many acquisition candidates.
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
• AdCare is executing an aggressive acquisition strategy – The company has begun buying skilled nursing facilities from independent operators, with the acquisition target calling for optimization potential and a reasonable price. According to a recent press release, 54 facilities have been put under contract since the campaign began. AdCare has been careful to avoid states with unhealthy economies, and has focused on the Southeast, Southwest, and Midwest.
• AdCare is improving the metrics associated with the acquired facilities – Once an appropriate property is acquired, AdCare increases the acuity level of the services it offers, increasing the Medicare census and the resulting reimbursement rates. In addition, AdCare identifies and implements various operational efficiencies, improving the bottom line. As a result, the company’s Medicare census has increased by 37.5% at acquired facilities. AdCare has also been able to offset recent cuts in Medicare reimbursements.
• AdCare revenues are increasing at record rates – Third quarter 2011 revenues increased a record 208% over the prior year, to $40.9 million, due to the company’s acquisition strategy and operation optimization results. Given the company’s success to date, and the announced acquisitions yet to close, management guidance points to annual recurring revenue of over $300 million, a 460% increase over 2010 levels. And this doesn’t include acquisitions not yet announced.
• AdCare has unique growth opportunities due to a fragmented but growing industry – The overall value of the long-term care market grew from $186 billion in 2005 to $258 billion in 2010, and is expected to continue to grow at over 6% annually. The skilled nursing care market, AdCare’s acquisition focus, is the biggest market segment. The long-term care market is extremely fragmented, with roughly 80% of nursing homes being privately owned single facilities, providing many acquisition candidates.
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, January 27, 2012
Local Corp. (LOCM) Releases Optimized, Mobile-Enabled Search Site
Today, Local Corp., a leading online local media company, announced that they have released an updated and optimized mobile-enabled version of its flagship local search site, Local.com.
The mobile site allows users to quickly and easily search for local products and services from their mobile device. Users can use the site’s geo-tracking technology to search for businesses near them based on their current physical location.
The new optimized site features a simplified user interface and “app-like” navigation, as well as an easy click-to-call function. Users can use the site to see relevant local business information, including ratings, reviews, photos, logos and maps and directions to quickly locate their desired destination.
“Consumers are accessing local information from their mobile devices more than ever before. Mobile visits represent nine percent of the total visits to Local.com, which is up nearly tenfold from a year ago,” said Mark Wallin, vice president, product, Local Corp. “The optimized version of our mobile site provides our users with a superior local search experience that they can use anytime, wherever they are.”
Overall, more than 88 million mobile subscribers accessed local content on mobile devices in September 2011, which was up 28 percent from a year ago
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The mobile site allows users to quickly and easily search for local products and services from their mobile device. Users can use the site’s geo-tracking technology to search for businesses near them based on their current physical location.
The new optimized site features a simplified user interface and “app-like” navigation, as well as an easy click-to-call function. Users can use the site to see relevant local business information, including ratings, reviews, photos, logos and maps and directions to quickly locate their desired destination.
“Consumers are accessing local information from their mobile devices more than ever before. Mobile visits represent nine percent of the total visits to Local.com, which is up nearly tenfold from a year ago,” said Mark Wallin, vice president, product, Local Corp. “The optimized version of our mobile site provides our users with a superior local search experience that they can use anytime, wherever they are.”
Overall, more than 88 million mobile subscribers accessed local content on mobile devices in September 2011, which was up 28 percent from a year ago
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Emulex (ELX) Posts Q2 Fiscal 2012 Financial and Business Results
Emulex Corp., a leading provider of converged networking solutions for the IT industry, today announced its financial results and operational achievements for its second quarter of fiscal 2012 ended January 1, 2012.
The company reported a 13 percent increase in second-quarter net revenues to $128.7 million compared to total net revenues of $114.0 million reported for second quarter fiscal 2011.
Second-quarter net income on a GAAP basis was $15.0 million, or $0.17 per diluted share, compared to a GAAP net loss of $41.0 million, or $(0.47) per share, in the second quarter of last year. Non-GAAP net income for the second quarter of fiscal 2012 was $22.6 million, or $0.26 per diluted share, a 69 percent increase from the $13.4 million reported in the comparable quarter of fiscal 2011.
GAAP operating income was $11.8 million, or 9 percent of total net revenues; non-GAAP operating income of $24.5 million represents 19 percent of total net revenues.
Emulex reported GAAP gross margins of 59 percent and non-GAAP gross margins of 63 percent.
Cash, cash equivalents and investments at the end of the second quarter were $191.7 million
“Our focus on operational excellence is reflected in our results as we once again exceeded the high-end of our revenues and earnings guidance. December was our fourth consecutive quarter of double digit year-over-year revenue growth, as we continued to drive market share gains in our core business,” CEO Jim McCluney stated in the press release. “Looking forward, we believe we are exceptionally well positioned to deliver increased shareholder value as we continue to build on this momentum.”
Second-quarter business highlights include the delivery of three new I/O connectivity solutions for HP Integrity servers; continued 10GbE market share gains for the fifth straight quarter; the announcement of the Emulex Extra Program, a major initiative to support customers and partners; and the introduction of OneCommand(R) Vision 2.0, a proactive I/O performance and availability management for cloud and virtualized data center environments.
The company also provided guidance for its third fiscal quarter ending April 1, 2012. For the third quarter of fiscal 2012, Emulex forecasts total net revenues in the range of $121 million-$125 million; non-GAAP earnings per diluted share between $0.17 and $0.19; and GAAP earnings per diluted share between $0.05 and $0.07.
For more information visit www.Emulex.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company reported a 13 percent increase in second-quarter net revenues to $128.7 million compared to total net revenues of $114.0 million reported for second quarter fiscal 2011.
Second-quarter net income on a GAAP basis was $15.0 million, or $0.17 per diluted share, compared to a GAAP net loss of $41.0 million, or $(0.47) per share, in the second quarter of last year. Non-GAAP net income for the second quarter of fiscal 2012 was $22.6 million, or $0.26 per diluted share, a 69 percent increase from the $13.4 million reported in the comparable quarter of fiscal 2011.
GAAP operating income was $11.8 million, or 9 percent of total net revenues; non-GAAP operating income of $24.5 million represents 19 percent of total net revenues.
Emulex reported GAAP gross margins of 59 percent and non-GAAP gross margins of 63 percent.
Cash, cash equivalents and investments at the end of the second quarter were $191.7 million
“Our focus on operational excellence is reflected in our results as we once again exceeded the high-end of our revenues and earnings guidance. December was our fourth consecutive quarter of double digit year-over-year revenue growth, as we continued to drive market share gains in our core business,” CEO Jim McCluney stated in the press release. “Looking forward, we believe we are exceptionally well positioned to deliver increased shareholder value as we continue to build on this momentum.”
Second-quarter business highlights include the delivery of three new I/O connectivity solutions for HP Integrity servers; continued 10GbE market share gains for the fifth straight quarter; the announcement of the Emulex Extra Program, a major initiative to support customers and partners; and the introduction of OneCommand(R) Vision 2.0, a proactive I/O performance and availability management for cloud and virtualized data center environments.
The company also provided guidance for its third fiscal quarter ending April 1, 2012. For the third quarter of fiscal 2012, Emulex forecasts total net revenues in the range of $121 million-$125 million; non-GAAP earnings per diluted share between $0.17 and $0.19; and GAAP earnings per diluted share between $0.05 and $0.07.
For more information visit www.Emulex.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Investors Lovin’ It as McDonald’s Corp. (MCD) Hits $100
McDonald’s recently reported very strong Q4 results and having broken through the $100 mark on the share price recently, investors across the board are taking a strong look at this globally recognized brand’s solid profitability model, continued innovation and clear ability to deliver sustained growth. With MCD taking home the title of best performing stock in the Dow for 2011 and a healthy increase of some 33% in the share price for the year, it is no wonder everyone is taking a closer look at this success story.
Chief among the data points:
• Net Income for Q4 was up roughly 11% over the previous year to $1.38B, or Diluted EPS of $1.33/share, edging out the lower projections by analysts in the $1.29-1.30 range
• Sales Volume up 5.6% across the board (US 7.1%, Europe 7.3% and Asia Pacific/Mid East/Africa 6.9%)
• Revenue up 10% to $6.82B (just over the $6.81B projection)
• 16.54% increase annually in the rate of earnings since the Mar 2009 $50 share price
• Dividend yield of 2.8%, or $2.80/share, up every year since the Company went public in 1965 at $22.50/share
• PE ratio of 19.37; forward PE of 17.23; currently trading at around 7.5x book value
In many ways the stressed global economic landscape has reopened a classic dynamic and MCD has been able to make the best of it, leveraging strong market presence, brand identity, new menu choices tailored to the specific operating markets or larger global taste trends, the brilliant marketing the Company is known for, and the careful redesign/improvement of restaurants. It is no secret that the economy of scale MCD has created also plays a hand in profitability and the Company has been able to successfully push the model into just about every market on earth. As pocket books around the world tighten for various income levels, more and more people are turning to the convenient low-cost, high-value offerings of McDonald’s.
CEO of MCD, Jim Skinner, noted that the tremendous capacity to expand the physical footprint through new openings and improvements to existing infrastructure (some $2.9B in capital expenditures) possessed by MCD, should see another 1300 locations open up in the coming year (adding to an already massive 33.5k plus location footprint) and the re-imaging of some 2,400 restaurants. Emerging markets show strong potential and the Asia Pacific/Mid East/Africa segment is now 22% of revenue, up 14% in just five years. Europe is playing into the trend extremely well, as confirmed by an MCD statement that the 9% increase in revenue for Europe, which accounts for 40% of revenue, up a whopping 36% from five years ago, occurred despite direct contention with economic uncertainty.
Even with the massive run to its current position, MCD still retains a strong valuation for all of the observable reasons, even to long-term investors. Indeed, the presence of McDonald’s is so strong that pricing methodologies and strategies employed by the Company are routinely copied by other operators in the industry. A continued bevy of novel items, from McCafe drinks and premium coffees that penetrate parallel markets, to healthy items like fruit smoothies and wraps, keeps setting the fast food giant apart from competitors and the momentum amassed by the Company is truly impressive in its operating space.
Projections in a recent press release do indicate that rising commodity prices in US/Europe will impact profitability (up roughly 6% in 2011); however, with store traffic setting an all-time record of 68M visits per day, MCD is ready to strike hard and fast. There isn’t much skepticism floating around about MCD management’s ability to continue executing their winning strategy and despite rising commodity prices (which competitors also face), the Company has been able to move in higher margin items while successfully passing price hikes through to the consumer level. Analysts will be keen to see how MCD handles raw input cost increases and whether or not price increases will be implemented in future to deal with them.
For more information on the Company please visit the McDonald’s Corporate Site at http://goo.gl/CCH03
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Chief among the data points:
• Net Income for Q4 was up roughly 11% over the previous year to $1.38B, or Diluted EPS of $1.33/share, edging out the lower projections by analysts in the $1.29-1.30 range
• Sales Volume up 5.6% across the board (US 7.1%, Europe 7.3% and Asia Pacific/Mid East/Africa 6.9%)
• Revenue up 10% to $6.82B (just over the $6.81B projection)
• 16.54% increase annually in the rate of earnings since the Mar 2009 $50 share price
• Dividend yield of 2.8%, or $2.80/share, up every year since the Company went public in 1965 at $22.50/share
• PE ratio of 19.37; forward PE of 17.23; currently trading at around 7.5x book value
In many ways the stressed global economic landscape has reopened a classic dynamic and MCD has been able to make the best of it, leveraging strong market presence, brand identity, new menu choices tailored to the specific operating markets or larger global taste trends, the brilliant marketing the Company is known for, and the careful redesign/improvement of restaurants. It is no secret that the economy of scale MCD has created also plays a hand in profitability and the Company has been able to successfully push the model into just about every market on earth. As pocket books around the world tighten for various income levels, more and more people are turning to the convenient low-cost, high-value offerings of McDonald’s.
CEO of MCD, Jim Skinner, noted that the tremendous capacity to expand the physical footprint through new openings and improvements to existing infrastructure (some $2.9B in capital expenditures) possessed by MCD, should see another 1300 locations open up in the coming year (adding to an already massive 33.5k plus location footprint) and the re-imaging of some 2,400 restaurants. Emerging markets show strong potential and the Asia Pacific/Mid East/Africa segment is now 22% of revenue, up 14% in just five years. Europe is playing into the trend extremely well, as confirmed by an MCD statement that the 9% increase in revenue for Europe, which accounts for 40% of revenue, up a whopping 36% from five years ago, occurred despite direct contention with economic uncertainty.
Even with the massive run to its current position, MCD still retains a strong valuation for all of the observable reasons, even to long-term investors. Indeed, the presence of McDonald’s is so strong that pricing methodologies and strategies employed by the Company are routinely copied by other operators in the industry. A continued bevy of novel items, from McCafe drinks and premium coffees that penetrate parallel markets, to healthy items like fruit smoothies and wraps, keeps setting the fast food giant apart from competitors and the momentum amassed by the Company is truly impressive in its operating space.
Projections in a recent press release do indicate that rising commodity prices in US/Europe will impact profitability (up roughly 6% in 2011); however, with store traffic setting an all-time record of 68M visits per day, MCD is ready to strike hard and fast. There isn’t much skepticism floating around about MCD management’s ability to continue executing their winning strategy and despite rising commodity prices (which competitors also face), the Company has been able to move in higher margin items while successfully passing price hikes through to the consumer level. Analysts will be keen to see how MCD handles raw input cost increases and whether or not price increases will be implemented in future to deal with them.
For more information on the Company please visit the McDonald’s Corporate Site at http://goo.gl/CCH03
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Canadian Solar, Inc. (CSIQ) Announces Agreement with Al Fahad Group for Significant Solar PV Project in Abu Dhabi
Canadian Solar, Inc. recently announced that it has forged an agreement with the Al Fahad Group. Canadian Solar, one of the largest solar companies in the world, will begin supplying more than 1.5 MW of its solar modules to the Al Fahad Group under the new agreement. The Al Fahad Group is a diversified conglomerate with proficiency in homeland security, defense & intelligence, networking & communications, and power. Al Fahad delivers tailored, end-to-end solutions to clients across a broad spectrum of industries and government agencies.
Canadian Solar’s CS5A-M solar modules will be used in one of the largest solar PV projects in Abu Dhabi, which is being spearheaded by the Al Fahad Group. This governmental venture was agreed upon during the recent World Future Energy Summit (WFES) in Abu Dhabi. Canadian Solar’s CS5A-M modules are ideally settled for the challenging local climate conditions in Abu Dhabi, and it was this factor, coupled with Canadian Solar’s track record of reliability, high quality and proven performance, that led the Al Fahad Group to select Canadian Solar for the project.
Together with the Al Fahad Group, Canadian Solar will further build its presence in the Middle East market for sustainable energy solutions, tapping into the great potential in the Middle East – particularly in the United Arab Emirates – for the developing solar market. The government’s commitment and financial system, coupled with forward thinking key proponents like the Al Fahad Group, make the Middle East a prime location for developing renewable energies like solar.
Canadian Solar is a leading vertically integrated supplier of ingot, wafer, solar cell, solar module and other solar applications, and the company specializes in designing, manufacturing and delivering solar products and solar system solutions to both on-grid and off-grid customers across the globe. Canadian Solar provides environmentally friendly and cost-effective premium solar solutions to foster worldwide, sustainable development.
For further information about the company, visit www.candiansolar.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Canadian Solar’s CS5A-M solar modules will be used in one of the largest solar PV projects in Abu Dhabi, which is being spearheaded by the Al Fahad Group. This governmental venture was agreed upon during the recent World Future Energy Summit (WFES) in Abu Dhabi. Canadian Solar’s CS5A-M modules are ideally settled for the challenging local climate conditions in Abu Dhabi, and it was this factor, coupled with Canadian Solar’s track record of reliability, high quality and proven performance, that led the Al Fahad Group to select Canadian Solar for the project.
Together with the Al Fahad Group, Canadian Solar will further build its presence in the Middle East market for sustainable energy solutions, tapping into the great potential in the Middle East – particularly in the United Arab Emirates – for the developing solar market. The government’s commitment and financial system, coupled with forward thinking key proponents like the Al Fahad Group, make the Middle East a prime location for developing renewable energies like solar.
Canadian Solar is a leading vertically integrated supplier of ingot, wafer, solar cell, solar module and other solar applications, and the company specializes in designing, manufacturing and delivering solar products and solar system solutions to both on-grid and off-grid customers across the globe. Canadian Solar provides environmentally friendly and cost-effective premium solar solutions to foster worldwide, sustainable development.
For further information about the company, visit www.candiansolar.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, January 26, 2012
Emulex Corp. (ELX) is “One to Watch”
In the world of Information Technology, connectivity is the market behind the market, and it’s growing every day. Connectivity is what has made IT an indispensable foundational element of virtually every major business, by allowing a host of different IT machines and networks of machines to think and act together. And at the very heart of IT connectivity are the devices that make it all possible, the adapters, controllers, switches, and bridges, along with the associated support software. Since IT connectivity tends to be a behind-the-scenes industry, it doesn’t get the exposure more common with high-visibility ends of the business, but therein hides the opportunity.
Emulex, based in Cosa Mesa, California, is a leader in converged networking solutions for data centers, essentially products for connecting servers, networks, and storage devices. The company’s solutions are used and offered by some of the biggest names in the server and storage OEM industry, including Cisco, Dell, Fujitsu, Hitachi, HP, IBM, NEC, and Oracle, and have been time-tested in the world’s most demanding IT environments.
Emulex products include connectivity software, Fibre Channel host bus adapters, Fibre Channel over Ethernet converged network adapters, embedded storage switches, storage I/O controller and SAN storage switch products. To someone outside the IT world, it’s all pretty esoteric, but Emulex products play a critical role in keeping some very big names up and running, and the company partners with the best. For example, Emulex and Cisco have worked collaboratively on technology that transforms data center networks into an agile infrastructure.
It’s one of the reasons for the big rise in share price over the past month, as the company announced faster than expected recovery of its production operations in Thailand, following some of the worst flooding in decades. The educated marketplace knows that the demand is there.
For additional information, visit the company’s website at www.Emulex.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Emulex, based in Cosa Mesa, California, is a leader in converged networking solutions for data centers, essentially products for connecting servers, networks, and storage devices. The company’s solutions are used and offered by some of the biggest names in the server and storage OEM industry, including Cisco, Dell, Fujitsu, Hitachi, HP, IBM, NEC, and Oracle, and have been time-tested in the world’s most demanding IT environments.
Emulex products include connectivity software, Fibre Channel host bus adapters, Fibre Channel over Ethernet converged network adapters, embedded storage switches, storage I/O controller and SAN storage switch products. To someone outside the IT world, it’s all pretty esoteric, but Emulex products play a critical role in keeping some very big names up and running, and the company partners with the best. For example, Emulex and Cisco have worked collaboratively on technology that transforms data center networks into an agile infrastructure.
It’s one of the reasons for the big rise in share price over the past month, as the company announced faster than expected recovery of its production operations in Thailand, following some of the worst flooding in decades. The educated marketplace knows that the demand is there.
For additional information, visit the company’s website at www.Emulex.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SMTP (SMTP) Announces Strategy to Extend Market Reach to Target “Burgeoning” European Market
SMTP Inc., a leading provider of cloud-based e-mail deliverability services, today announced its plans to expand across Western Europe with guidance from Jorge Casas, the company’s newly appointed director of Business Development and Customer Service.
“Our strategy reflects the direction and globalization of the marketplace, and reinforces our position as a leading Micro Multinational enterprise,” Semyon Dukach, CEO of SMTP stated in the press release. “We operate today in a global business community, where technology and communications empowers organizations like SMTP to thrive by virtually transcending national borders.”
SMTP currently works with more than 10,000 customers in 150 countries, and recently reported a 70 percent increase in net revenue for the third quarter of 2011. The company reports that it recognizes increasing opportunity for its deliverability services overseas, which supports estimates that the global market for commercial e-mail is more than $60 billion in sales.
Industry analysts say approximately 15 percent of e-mail is undelivered in Europe, and that marketers targeting this area must advance their e-mail marketing programs to succeed.
“The largest component to Internet e-mail marketing investment is in effective delivery, which is the core element of our service offering,” Dukach stated. “Our 24/7, global support team is available to customers worldwide to help them navigate the myriad intricacies of high-volume and transactional e-mail delivery.”
Casas’ previously served as multilingual customer service and export supervisor for Prestolite Electric LTD from 2009 to 2012, where he was the company’s interface for all customer service-related matters serving France, Southern Europe and Maghreb.
For more information, visit www.smtp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“Our strategy reflects the direction and globalization of the marketplace, and reinforces our position as a leading Micro Multinational enterprise,” Semyon Dukach, CEO of SMTP stated in the press release. “We operate today in a global business community, where technology and communications empowers organizations like SMTP to thrive by virtually transcending national borders.”
SMTP currently works with more than 10,000 customers in 150 countries, and recently reported a 70 percent increase in net revenue for the third quarter of 2011. The company reports that it recognizes increasing opportunity for its deliverability services overseas, which supports estimates that the global market for commercial e-mail is more than $60 billion in sales.
Industry analysts say approximately 15 percent of e-mail is undelivered in Europe, and that marketers targeting this area must advance their e-mail marketing programs to succeed.
“The largest component to Internet e-mail marketing investment is in effective delivery, which is the core element of our service offering,” Dukach stated. “Our 24/7, global support team is available to customers worldwide to help them navigate the myriad intricacies of high-volume and transactional e-mail delivery.”
Casas’ previously served as multilingual customer service and export supervisor for Prestolite Electric LTD from 2009 to 2012, where he was the company’s interface for all customer service-related matters serving France, Southern Europe and Maghreb.
For more information, visit www.smtp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Digirad Corp. (DRAD) Garners CE Mark Approval for its Cardius® X-ACT Imaging System
Digirad, a leading supplier of diagnostic imaging products and personnel and equipment leasing services, announced that it has been granted Conformitee Europeene (CE) Mark approval for the Cardius® X-ACT imaging system. This advanced, solid-state camera system makes earlier disease detection possible through increased diagnostic accuracy. Obtaining CE Mark approval will enable Digirad to manufacture and market the Cardius X-ACT system in the European Union.
Digirad additionally announced that it has signed a distribution agreement with Epsilon Elektronik, a Turkish company that is part of the Istanbul-based Bozlu Group. This agreement is part of Digirad’s strategy to build out a targeted international selling network. Digirad signed a similar agreement last year with Southern Scientific, a UK-based company that is already implementing the use of an ergo™ portable solid-state camera at the Manchester Royal Infirmary.
Part of Digirad’s international growth strategy is to build a network of top distributors in targeted markets, where the demand for flexible imaging products like the X-ACT is steadily growing. The company projects that the flexibility, lower overall costs and potential for improved clinical outcomes will make its expanding line of camera products attractive in the international market. Securing other distribution agreements will be key in Digirad’s endeavor to more meaningfully tap into burgeoning markets for dedicated cardiac and portable nuclear imaging.
The Cardius X-ACT imaging system considerably reduces artifacts in images caused by overlying tissues. This is accomplished through X-ACT’s low-dose volume-computed tomography attenuation correction system. Digirad anticipates that its X-ACT imaging system, ergo™ flexible imaging camera and future camera models will be well received in the international market, providing new clinical information that will increase the benefit of nuclear cardiology procedures, raise industry standards for SPECT system performance and improve outcomes at an accessible price point.
Digirad previously received FDA clearance to market the Cardius X-ACT imaging system in the United States and also obtained CE Mark and FDA clearance to market the ergo portable solid-state camera.
For further information about the company, visit www.digirad.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Digirad additionally announced that it has signed a distribution agreement with Epsilon Elektronik, a Turkish company that is part of the Istanbul-based Bozlu Group. This agreement is part of Digirad’s strategy to build out a targeted international selling network. Digirad signed a similar agreement last year with Southern Scientific, a UK-based company that is already implementing the use of an ergo™ portable solid-state camera at the Manchester Royal Infirmary.
Part of Digirad’s international growth strategy is to build a network of top distributors in targeted markets, where the demand for flexible imaging products like the X-ACT is steadily growing. The company projects that the flexibility, lower overall costs and potential for improved clinical outcomes will make its expanding line of camera products attractive in the international market. Securing other distribution agreements will be key in Digirad’s endeavor to more meaningfully tap into burgeoning markets for dedicated cardiac and portable nuclear imaging.
The Cardius X-ACT imaging system considerably reduces artifacts in images caused by overlying tissues. This is accomplished through X-ACT’s low-dose volume-computed tomography attenuation correction system. Digirad anticipates that its X-ACT imaging system, ergo™ flexible imaging camera and future camera models will be well received in the international market, providing new clinical information that will increase the benefit of nuclear cardiology procedures, raise industry standards for SPECT system performance and improve outcomes at an accessible price point.
Digirad previously received FDA clearance to market the Cardius X-ACT imaging system in the United States and also obtained CE Mark and FDA clearance to market the ergo portable solid-state camera.
For further information about the company, visit www.digirad.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, January 25, 2012
Premier Exhibitions, Inc. (PRXI) is “One to Watch”
Touring exhibitions are becoming an important source of traffic for museums and exhibition centers, but putting together and deploying such traveling exhibitions, on a worldwide basis, is daunting. Premier Exhibitions is a Georgia based company that has become a recognized leader in developing and managing such exhibitions, involving authentic artifacts presented in stunning environments. The company serves museums, exhibition centers, and non-traditional venues. To date, Premier’s exhibit titled Titanic: The Artifact Exhibition, presented through the company’s wholly owned subsidiary RMS Titanic, Inc., has been seen by more than 18 million visitors, and continues to break attendance records.
Premier Exhibitions is constantly building its exhibition portfolio, focusing on the most compelling properties in science, technology, social history, and the fine arts. But Premier’s strength is that they do far more than simply show fascinating artifacts. They structure the exhibition to tell a story, as in the Titanic exhibition which takes the visitor all the way from the ships initial construction in Belfast to the gangway of the ship as it gets ready for its maiden voyage. Visitors are able to walk down the ship’s first class hallway, visit a third-class cabin, and view the night sky as it appeared exactly when the ship sank in April of 1912. The upcoming 100th anniversary of that event is expected to draw record crowds.
In the case of the Titanic artifacts, Premier was granted rights to the wreck of the Titanic by a U.S. Federal District Court order, including the exclusive rights to recover artifacts from the wreck site. To date, more than 5,000 artifacts have been brought up and given new life, offering people all over the world an exciting and personal look at one of history’s most unforgettable stories.
For additional information, visit the company’s website at www.PRXI.com, and get more information on the Titanic exhibit at www.TitanicScience.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Premier Exhibitions is constantly building its exhibition portfolio, focusing on the most compelling properties in science, technology, social history, and the fine arts. But Premier’s strength is that they do far more than simply show fascinating artifacts. They structure the exhibition to tell a story, as in the Titanic exhibition which takes the visitor all the way from the ships initial construction in Belfast to the gangway of the ship as it gets ready for its maiden voyage. Visitors are able to walk down the ship’s first class hallway, visit a third-class cabin, and view the night sky as it appeared exactly when the ship sank in April of 1912. The upcoming 100th anniversary of that event is expected to draw record crowds.
In the case of the Titanic artifacts, Premier was granted rights to the wreck of the Titanic by a U.S. Federal District Court order, including the exclusive rights to recover artifacts from the wreck site. To date, more than 5,000 artifacts have been brought up and given new life, offering people all over the world an exciting and personal look at one of history’s most unforgettable stories.
For additional information, visit the company’s website at www.PRXI.com, and get more information on the Titanic exhibit at www.TitanicScience.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Chanticleer Holdings, Inc. (CCLR) Continues Australian Expansion, Opens Campbelltown Location in Sydney SW Area
Chanticleer Holdings, the company spearheading an international roll out of the popular Hooters brand restaurant, recently announced further expansion in Australia with the opening of a new location in Campbelltown, following fast on the heels of the recent Penrith opening only six months ago.
Australian operations for Hooters began with the flagship Hooters of Parramatta location, ideally situated on major thoroughfare James Ruse Drive in the thriving Rosehill suburb of New South Wales, just opposite the massive Rosehill Gardens Racecourse (home to the Sydney Turf Club and some of Australia’s premier thoroughbred racing). This first Hooters location in Australia sits in the heart of an area already extremely well known for sports and entertainment.
Check out Chanticleer’s Promotional Video (http://goo.gl/nL8j7) to get a little closer to Hooters Australia, which is quickly becoming one of the hottest destinations in the Sydney area.
Like all Hooters restaurants, the new Campbelltown location serves up a huge menu of delicious American fast-casual cuisine, backed up by a wide selection of ice cold beer and a variety of spirits, all with non-stop sports action available via state-of-the-art entertainment systems/displays, making for an unbeatable dining experience that Hooters patrons around the globe have come to expect. It is this reputation for great dining and atmosphere, combined with the gorgeous Australian Hooters Girls, that makes the venue such a compelling draw.
As with previous openings, great care was exercised in the selection of a premium site and the Campbelltown Hooters is no exception. Targeting the growing SW Sydney area, the Campbelltown Hooters also balances out the Penrith and NSW locations (which are NW and W respectively), affording solid coverage of some of Sydney’s most attractive markets.
CEO of CCLR, Michael Pruitt, was keen to point out that this is the first joint venture-developed restaurant with Morney Schlebusch’s team, COO of Hooters Australia (license acquired in 2009), calling the opening a key milestone for CCLR’s execution of their international campaign. Pruitt drove home the extensibility of the brand and praised Morney for his superb work nurturing the Hooters brand in Australia to fruition.
Morney emphasized the tremendous groundswell of excitement from the local community prior to opening and drove home the importance of this receptivity to the brand as a key factor in the core growth strategy for international and emerging markets. Citing the Company’s three South Africa locations, Morney pledged to work hand-in-hand with the Company to breed market spanning innovations and this is no small talk coming from Schlebusch, who has over two decades of frontline experience in the industry.
All of the Hooters girls and staff for the Campbelltown location are from the SW region, driving home another key facet of the successful Hooters strategy, which is giving back to the community while cementing the location as a warm, inviting fixture of the local landscape.
For more information on Chanticleer Holdings, Inc. and Hooters of America, visit http://www.ChanticleerHoldings.com and http://www.Hooters.com
For more information on Hooters Australia, visit http://www.HootersAustralia.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Australian operations for Hooters began with the flagship Hooters of Parramatta location, ideally situated on major thoroughfare James Ruse Drive in the thriving Rosehill suburb of New South Wales, just opposite the massive Rosehill Gardens Racecourse (home to the Sydney Turf Club and some of Australia’s premier thoroughbred racing). This first Hooters location in Australia sits in the heart of an area already extremely well known for sports and entertainment.
Check out Chanticleer’s Promotional Video (http://goo.gl/nL8j7) to get a little closer to Hooters Australia, which is quickly becoming one of the hottest destinations in the Sydney area.
Like all Hooters restaurants, the new Campbelltown location serves up a huge menu of delicious American fast-casual cuisine, backed up by a wide selection of ice cold beer and a variety of spirits, all with non-stop sports action available via state-of-the-art entertainment systems/displays, making for an unbeatable dining experience that Hooters patrons around the globe have come to expect. It is this reputation for great dining and atmosphere, combined with the gorgeous Australian Hooters Girls, that makes the venue such a compelling draw.
As with previous openings, great care was exercised in the selection of a premium site and the Campbelltown Hooters is no exception. Targeting the growing SW Sydney area, the Campbelltown Hooters also balances out the Penrith and NSW locations (which are NW and W respectively), affording solid coverage of some of Sydney’s most attractive markets.
CEO of CCLR, Michael Pruitt, was keen to point out that this is the first joint venture-developed restaurant with Morney Schlebusch’s team, COO of Hooters Australia (license acquired in 2009), calling the opening a key milestone for CCLR’s execution of their international campaign. Pruitt drove home the extensibility of the brand and praised Morney for his superb work nurturing the Hooters brand in Australia to fruition.
Morney emphasized the tremendous groundswell of excitement from the local community prior to opening and drove home the importance of this receptivity to the brand as a key factor in the core growth strategy for international and emerging markets. Citing the Company’s three South Africa locations, Morney pledged to work hand-in-hand with the Company to breed market spanning innovations and this is no small talk coming from Schlebusch, who has over two decades of frontline experience in the industry.
All of the Hooters girls and staff for the Campbelltown location are from the SW region, driving home another key facet of the successful Hooters strategy, which is giving back to the community while cementing the location as a warm, inviting fixture of the local landscape.
For more information on Chanticleer Holdings, Inc. and Hooters of America, visit http://www.ChanticleerHoldings.com and http://www.Hooters.com
For more information on Hooters Australia, visit http://www.HootersAustralia.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
CAMAC Energy (CAK) Awarded Contract to Operate Offshore Exploration Blocks in Highly Sought-after African Province
CAMAC Energy Inc., an energy company engaged in the exploration, development and production of oil and gas, announced its agreement with the Gambian Ministry of Petroleum (on behalf of the Government of the Republic of The Gambia) in which the company was awarded the contract to be the operator of two offshore exploration blocks in water depths between 600-1,000 meters.
Per the agreement, CAMAC Energy will operate blocks A2 and A5, for which it holds an 85 percent interest in the blocks, which cover 2,666 square kilometers.
The agreement is a significant achievement for the company, reflecting the opportunity to operate in a highly favored province in West Africa and emphasizing the company’s position in the market.
“We are extremely pleased to be awarded these two blocks. Gambia’s blocks A2 and A5 represent highly sought after assets in one of the world’s most exciting hydrocarbon provinces, the West African Transform Margin. Today’s announcement demonstrates additional progress in our frontier exploration strategy. It also reaffirms the company’s reputation as a value added oil and gas partner to National Oil Companies in Africa,” CAMAC Energy chairman and CEO Dr. Kase Lawal stated in the press release.
The two exploration blocks are located in the highly prospective West African Transform Margin, which is home to several recent major discoveries in Ghana and Sierra Leone. The presence of hydrocarbons has been established in the area, and recent extensive 3D seismic shots have revealed several material prospects and leads.
According to African Petroleum Corporation Limited’s (NSX:AOQ) third-party estimates, the Alhamdulilah prospect has potential mean unrisked resources of approximately 500 million barrels.
The agreement is subject to submission of an Environmental Impact Assessment (EIA) and signing of final petroleum exploration licenses within 90 days. CAMAC has submitted the EIA report, and signing of the license documents is expected in the next few weeks.
For more information visit www.camacenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Per the agreement, CAMAC Energy will operate blocks A2 and A5, for which it holds an 85 percent interest in the blocks, which cover 2,666 square kilometers.
The agreement is a significant achievement for the company, reflecting the opportunity to operate in a highly favored province in West Africa and emphasizing the company’s position in the market.
“We are extremely pleased to be awarded these two blocks. Gambia’s blocks A2 and A5 represent highly sought after assets in one of the world’s most exciting hydrocarbon provinces, the West African Transform Margin. Today’s announcement demonstrates additional progress in our frontier exploration strategy. It also reaffirms the company’s reputation as a value added oil and gas partner to National Oil Companies in Africa,” CAMAC Energy chairman and CEO Dr. Kase Lawal stated in the press release.
The two exploration blocks are located in the highly prospective West African Transform Margin, which is home to several recent major discoveries in Ghana and Sierra Leone. The presence of hydrocarbons has been established in the area, and recent extensive 3D seismic shots have revealed several material prospects and leads.
According to African Petroleum Corporation Limited’s (NSX:AOQ) third-party estimates, the Alhamdulilah prospect has potential mean unrisked resources of approximately 500 million barrels.
The agreement is subject to submission of an Environmental Impact Assessment (EIA) and signing of final petroleum exploration licenses within 90 days. CAMAC has submitted the EIA report, and signing of the license documents is expected in the next few weeks.
For more information visit www.camacenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Zogenix (ZGNX) Signs Joint Marketing and Technology Development Agreement with Battelle to Advance Development of DosePro® Drug Delivery Technology
Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that they have signed a non-binding letter of intent for an exclusive co-marketing and technology development option agreement with Battelle to advance the development and commercialization of Zogenix’s DosePro® drug. Battelle, one of the world’s largest independent research and development organizations, will work with Zogenix to offer DosePro needle-free drug delivery technology to pharmaceutical and biotechnology firms for new commercial out-licensing opportunities.
Zogenix’s DosePro patented technology, which has United States and Europe regulatory approvals, enables needle-free medication delivery under the skin by using a small amount of compressed gas to deliver a liquid version of medication through the skin. It is the only commercially available, single-use, disposable, needle-free, subcutaneous delivery technology in the world.
“We recognize that DosePro can provide sustainable competitive advantages for many injectable drugs, especially biologics. With Battelle’s expertise in product development and strong relationships with biopharmaceutical companies, we can now match DosePro technology to drug candidates in a more efficient manner by providing customizable drug delivery solutions that can effectively deliver biologics, vaccines and other critical drugs. We believe this arrangement will accelerate entry into licensing agreements with major pharmaceutical companies,” said John Turanin, Vice President and General Manager, DosePro Technology, Zogenix in a press release.
The intent of this partnership is to help meet the needs of biopharmaceutical companies that want to offer more customizable platform technologies that create different products for increased efficacy, patient compliance and market share. Zogenix has completed prototype design for the product but hopes that further development in collaboration with Battelle will help to broaden the capability of the technology to deliver larger dose volumes, which are required for high-dose biological products.
“We believe DosePro features market-leading technology for the safe and effective delivery of biologics, especially high viscosity formulations, which is critically important to our customers. This collaboration will enhance our ability to extend our leadership in drug delivery technology development to create innovative solutions for the pharmaceutical industry,” said Barbara Kunz, President, Battelle Health and Life Sciences Global Business in the press statement.
For more information on Zogenix, visit www.zogenix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Zogenix’s DosePro patented technology, which has United States and Europe regulatory approvals, enables needle-free medication delivery under the skin by using a small amount of compressed gas to deliver a liquid version of medication through the skin. It is the only commercially available, single-use, disposable, needle-free, subcutaneous delivery technology in the world.
“We recognize that DosePro can provide sustainable competitive advantages for many injectable drugs, especially biologics. With Battelle’s expertise in product development and strong relationships with biopharmaceutical companies, we can now match DosePro technology to drug candidates in a more efficient manner by providing customizable drug delivery solutions that can effectively deliver biologics, vaccines and other critical drugs. We believe this arrangement will accelerate entry into licensing agreements with major pharmaceutical companies,” said John Turanin, Vice President and General Manager, DosePro Technology, Zogenix in a press release.
The intent of this partnership is to help meet the needs of biopharmaceutical companies that want to offer more customizable platform technologies that create different products for increased efficacy, patient compliance and market share. Zogenix has completed prototype design for the product but hopes that further development in collaboration with Battelle will help to broaden the capability of the technology to deliver larger dose volumes, which are required for high-dose biological products.
“We believe DosePro features market-leading technology for the safe and effective delivery of biologics, especially high viscosity formulations, which is critically important to our customers. This collaboration will enhance our ability to extend our leadership in drug delivery technology development to create innovative solutions for the pharmaceutical industry,” said Barbara Kunz, President, Battelle Health and Life Sciences Global Business in the press statement.
For more information on Zogenix, visit www.zogenix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics (VSTA) Taps Stem Cell Potential
When it comes to modern medicine, stem cells are seen as playing an increasingly important role, a role unmatched by anything else. Pluripotent stem cells, including induced pluripotent stem cells (adult cells that have been genetically reprogrammed to an embryonic stem cell-like state), are unique in their ability to differentiate into specialized cells, such as heart or muscle or nerve cells. As a result, they provide an important tool for medical research, treatment and drug development.
For example, pluripotent stem cells can play a substantial role in the discovery of creative new medicines that are more effective and safer for patients. They can also be used in the field of regenerative medicine, where various tissues and organs can be generated to replace damaged ones. In addition, given their ability to duplicate the functions of a whole host of other cells, stem cells are becoming important in all types of advanced biomedical research, and they are helping us understand the most basic workings of the human cell and human body.
In the case of VistaGen Therapeutics, stem cells are being used to help researchers and developers better predict, at the earliest stages of drug development, the effects of a drug candidate on human tissues, organs, and processes. Too often pharmaceutical companies spend huge amounts of money developing and marketing new drugs, only to find late in the game that the drug must be limited or completely withdrawn due to unforeseen adverse health effects, often relating to the heart. Since heart toxicity has been a factor in nearly a third of such drug withdrawals, VistaGen’s use of stem cell technology to produce a novel bioassay system with mature, functional human heart cells that can be used for early and accurate testing of such effects represents a major accomplishment in the field. VistaGen is also developing a novel bioassay system to rescue new drug candidates limited by liver toxicity, another major factor in drug withdrawals.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
For example, pluripotent stem cells can play a substantial role in the discovery of creative new medicines that are more effective and safer for patients. They can also be used in the field of regenerative medicine, where various tissues and organs can be generated to replace damaged ones. In addition, given their ability to duplicate the functions of a whole host of other cells, stem cells are becoming important in all types of advanced biomedical research, and they are helping us understand the most basic workings of the human cell and human body.
In the case of VistaGen Therapeutics, stem cells are being used to help researchers and developers better predict, at the earliest stages of drug development, the effects of a drug candidate on human tissues, organs, and processes. Too often pharmaceutical companies spend huge amounts of money developing and marketing new drugs, only to find late in the game that the drug must be limited or completely withdrawn due to unforeseen adverse health effects, often relating to the heart. Since heart toxicity has been a factor in nearly a third of such drug withdrawals, VistaGen’s use of stem cell technology to produce a novel bioassay system with mature, functional human heart cells that can be used for early and accurate testing of such effects represents a major accomplishment in the field. VistaGen is also developing a novel bioassay system to rescue new drug candidates limited by liver toxicity, another major factor in drug withdrawals.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, January 24, 2012
Brekford Corp. (BFDI) is “One to Watch”
When people talk about mobile technology, they are usually referring to the ubiquitous smart phone, along with the endlessly expanding string of applications and functionalities that are being loaded into it. What is often overlooked is the extensive and growing market of mobile technologies designed specifically for military and public safety vehicles. When it comes to the military, law enforcement, and public safety, the ability to capture, process, and communicate information is becoming an increasingly important part of the equation.
For over a decade, Brekford Corp., a Maryland based homeland security technology service provider, has been growing to become what is now a one-stop-shop for the U.S. military and various security and public safety agencies, offering a 360° suite of mobile computer and video technologies, vehicle upfitting services, and automated traffic safety enforcement solutions. Their reputation has been based upon a record of highly rugged and robust products, covering almost every operational requirement, together with all of the associated upfitting and support services.
In the case of law enforcement, fire and EMS services, all have their own special requirements for their various vehicles. Equipment must be able to perform a wide range of complex video and data processing and communication, while operating under the most extreme conditions. Brekford has defined itself as a single best resource for purchasing vehicles that are upfitted with the latest in ruggedized cutting-edge IT and communications, in addition to traditional hardware, such as lights and sirens.
An example of technology meeting the need is Brekford’s Automatic Traffic Enforcement systems or Automatic Photo Enforcement Systems. The Automated Traffic Enforcement (ATE) system is an enforcement technique where one or more motor vehicle sensors generate recorded images of motor vehicles traveling at speeds above a defined limit. Captured images are then processed and reviewed in an office environment, and violation notices are mailed to the registered owner of the identified vehicle.
Another reason for Brekford’s success is their financing, leasing, and buying options. For instance, with government budgets under increased pressures, coupled with a growing demand for public safety, the company’s leasing program is, in many cases, the ideal answer to get technology on the streets at the lowest price.
For more information, visit the company’s website at www.Brekford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
For over a decade, Brekford Corp., a Maryland based homeland security technology service provider, has been growing to become what is now a one-stop-shop for the U.S. military and various security and public safety agencies, offering a 360° suite of mobile computer and video technologies, vehicle upfitting services, and automated traffic safety enforcement solutions. Their reputation has been based upon a record of highly rugged and robust products, covering almost every operational requirement, together with all of the associated upfitting and support services.
In the case of law enforcement, fire and EMS services, all have their own special requirements for their various vehicles. Equipment must be able to perform a wide range of complex video and data processing and communication, while operating under the most extreme conditions. Brekford has defined itself as a single best resource for purchasing vehicles that are upfitted with the latest in ruggedized cutting-edge IT and communications, in addition to traditional hardware, such as lights and sirens.
An example of technology meeting the need is Brekford’s Automatic Traffic Enforcement systems or Automatic Photo Enforcement Systems. The Automated Traffic Enforcement (ATE) system is an enforcement technique where one or more motor vehicle sensors generate recorded images of motor vehicles traveling at speeds above a defined limit. Captured images are then processed and reviewed in an office environment, and violation notices are mailed to the registered owner of the identified vehicle.
Another reason for Brekford’s success is their financing, leasing, and buying options. For instance, with government budgets under increased pressures, coupled with a growing demand for public safety, the company’s leasing program is, in many cases, the ideal answer to get technology on the streets at the lowest price.
For more information, visit the company’s website at www.Brekford.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Rackwise (RACK), Intel (INTC) to Co-Market Newest Version of DCiM™ Software
Rackwise Inc., a company offering data center infrastructure management products and services, today announced that it will release the latest version of its core DCiM™ software product, the Rackwise® Data Center Manager (DCM), in April of 2012.
In accordance with its recent multi-year software integration and license agreement with Intel Corp., the two companies will jointly market the Rackwise® DCM version 3.6 product worldwide with an initial emphasis on the Asia-Pacific and European markets.
“We are extremely excited to make this announcement, marking the initial product launch pursuant to our agreements with Intel to develop and introduce ground-breaking capabilities for the data center infrastructure management market,” Rackwise CEO Guy A. Archbold stated in the press release. “The integration of device level data aggregation within our asset visualization, modeling, and analytics functions provides data center and infrastructure technology professionals powerful, state-of-the-art tools for real-time data management to maximize operational efficiencies and economic benefits.”
The Rackwise® DCM 3.6 will extend device level monitoring capabilities through integration of the Intel® DCM software solution and offer the first implementation of real-time data gathering and reporting capabilities built around enhanced temperature/power monitoring, and failure analysis.
These and other features will enable data center personnel and executives to monitor and manage advanced analytics related to capacity, energy management and potential failure modes; allow asset tracking and reporting at all levels of modules contained within the enclosure; and allow access to all levels of data modeled within the solution, including visualization of devices, modules, racks and floor-mounted equipment.
“The Intel® Data Center Manager combined with the Rackwise® DCM helps provide data center managers and executives extensive visibility into device level energy usage and thermal data which will enhance capacity planning, forecasting, performance monitoring and energy management for significant operational savings. The Rackwise® DCM’s extensive visualization, reporting and analytics platform combined with information from Intel® DCM will give data center personnel an unprecedented level of intelligent access and control over the physical and virtual assets within the data center,” Jeff Klaus, director of Data Center Solutions for Intel stated.
For more information visit www.rackwise.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
In accordance with its recent multi-year software integration and license agreement with Intel Corp., the two companies will jointly market the Rackwise® DCM version 3.6 product worldwide with an initial emphasis on the Asia-Pacific and European markets.
“We are extremely excited to make this announcement, marking the initial product launch pursuant to our agreements with Intel to develop and introduce ground-breaking capabilities for the data center infrastructure management market,” Rackwise CEO Guy A. Archbold stated in the press release. “The integration of device level data aggregation within our asset visualization, modeling, and analytics functions provides data center and infrastructure technology professionals powerful, state-of-the-art tools for real-time data management to maximize operational efficiencies and economic benefits.”
The Rackwise® DCM 3.6 will extend device level monitoring capabilities through integration of the Intel® DCM software solution and offer the first implementation of real-time data gathering and reporting capabilities built around enhanced temperature/power monitoring, and failure analysis.
These and other features will enable data center personnel and executives to monitor and manage advanced analytics related to capacity, energy management and potential failure modes; allow asset tracking and reporting at all levels of modules contained within the enclosure; and allow access to all levels of data modeled within the solution, including visualization of devices, modules, racks and floor-mounted equipment.
“The Intel® Data Center Manager combined with the Rackwise® DCM helps provide data center managers and executives extensive visibility into device level energy usage and thermal data which will enhance capacity planning, forecasting, performance monitoring and energy management for significant operational savings. The Rackwise® DCM’s extensive visualization, reporting and analytics platform combined with information from Intel® DCM will give data center personnel an unprecedented level of intelligent access and control over the physical and virtual assets within the data center,” Jeff Klaus, director of Data Center Solutions for Intel stated.
For more information visit www.rackwise.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Echo Therapeutics, Inc. (ECTE) Begins Clinical Trial of Its Glucose Monitoring System
Echo Therapeutics, Inc. is a transdermal medical device company. The company has a wealth of expertise in advanced skin permeation technology. It plans to use its technology platform for two important applications, needle-free drug delivery and a needle-free, wireless, transdermal continuous glucose monitoring system.
The company today announced that it is initiating a clinical study of its Symphony tCGM System in patients with both Type 1 and Type 2 diabetes. Following skin permeation using the company’s proprietary Prelude skin permeation device, a biosensor is placed on the permeated site. After a brief warm-up period, Symphony wirelessly transmits the patient’s glucose level every minute to a remote monitor. The monitor than tracks the glucose level and provides an alarm if the patient’s glucose levels move outside the doctor’s prescribed range for the patient.
The Symphony system is certainly an improvement over current methods. All existing FDA-approved continuous glucose monitoring systems are needle-based, requiring insertion of a sensor into the patient’s skin. This gives rise to the risks of infection, inflammation or bleeding at the insertion site.
Echo plans to enroll up to 25 patients with diabetes in the study. The intent is to compare data obtained from its Symphony tCGM System with both the YSI 2300 STAT Plus Glucose Analyzer and a commercially available professional use glucometer. The company expects to complete and report the results of the study in the fourth quarter of this year. It then plans to subsequently begin a separate study in critical care patients.
For additional information of Echo Therapeutics and its glucose monitoring system, please visit the company’s website at www.echotx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company today announced that it is initiating a clinical study of its Symphony tCGM System in patients with both Type 1 and Type 2 diabetes. Following skin permeation using the company’s proprietary Prelude skin permeation device, a biosensor is placed on the permeated site. After a brief warm-up period, Symphony wirelessly transmits the patient’s glucose level every minute to a remote monitor. The monitor than tracks the glucose level and provides an alarm if the patient’s glucose levels move outside the doctor’s prescribed range for the patient.
The Symphony system is certainly an improvement over current methods. All existing FDA-approved continuous glucose monitoring systems are needle-based, requiring insertion of a sensor into the patient’s skin. This gives rise to the risks of infection, inflammation or bleeding at the insertion site.
Echo plans to enroll up to 25 patients with diabetes in the study. The intent is to compare data obtained from its Symphony tCGM System with both the YSI 2300 STAT Plus Glucose Analyzer and a commercially available professional use glucometer. The company expects to complete and report the results of the study in the fourth quarter of this year. It then plans to subsequently begin a separate study in critical care patients.
For additional information of Echo Therapeutics and its glucose monitoring system, please visit the company’s website at www.echotx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, January 23, 2012
Biostar Pharmaceuticals, Inc. (BSPM) Secures Key R&D Cooperation Agreement with Chinese Military Organization
Today, Biostar Pharmaceuticals, a leading provider of pharmaceuticals and health supplements, like the Company’s popular OTC offering for chronic hepatitis B (Xin AoXing Oleanolic Acid Capsule), reported special selection (at a January 8th ceremony) by the PLA’s Fourth Military Medical University (FMMU) for cooperation in ongoing research and product development activities.
The FMMU has been a major force in the Chinese military medical landscape since its formation in 1954 (out of the 4th and 5th Military Medical Colleges), serving a vital role as one of only a handful of key institutions for training middle- to high-level medical personnel for the People’s Liberation Army. Currently, the FMMU is comprised of a variety of specialized areas, including basic and aerospace medicine, as well as nursing, pharmacology, biomedical engineering, stomatology research (oral diseases), military services and statistics. In addition to the several college buildings, the FMMU also operates the First and Second Affiliated General Hospitals, as well as the Stomatological Hospital.
Chairman and CEO of BSPM, Ronghua Wang, telegraphed shareholder excitement about the Company being selected as one of only nine Chinese pharma companies for such a prestigious cooperation agreement with the FMMU; noting Biostar’s lean architecture and vertically integrated business model, deep R&D competencies, manufacturing and marketing prowess. Wang reaffirmed the Company’s commitment to increasing shareholder value through expanded product range, improved sales volume and overall efficiency/profitability through periods of sustained growth.
The audience of some 3k doctors, professors and professional members of the Chinese medical community, including executives from over 500 pharma companies, listened intently as Wang detailed projected collaboration between BSPM and the FMMU in advancing the products covered under the agreement through Phase IV clinical trials. Wang also indicated that prescribed military guidelines would entail R&D for select products intended for use solely by the PRC and the FMMU’s three hospitals. The Zushima pain suppressant spray BSPM developed for the military is a good example of the approach as well as the results that will be employed moving forward.
Wang went on to extol the Company’s years of dedicated effort by BSPM personnel in nurturing strategic relationships with key universities throughout China, like the Shaanxi College of Traditional Chinese Medicine and Shaanxi University of Science and Technology, as well as the Northwest University College of Life Science. This diligent effort, in conjunction with the newly acquired FMMU cooperation, has positioned BSPM for unprecedented growth on the surging projections in the pharma sector.
Huge news for BSPM, being selected out of so many candidates in the FMMU’s rigorous screening process, and it all came down to the incredibly positive track record set by the Company in everything from R&D milestones to clinical trial completion and product efficacy.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The FMMU has been a major force in the Chinese military medical landscape since its formation in 1954 (out of the 4th and 5th Military Medical Colleges), serving a vital role as one of only a handful of key institutions for training middle- to high-level medical personnel for the People’s Liberation Army. Currently, the FMMU is comprised of a variety of specialized areas, including basic and aerospace medicine, as well as nursing, pharmacology, biomedical engineering, stomatology research (oral diseases), military services and statistics. In addition to the several college buildings, the FMMU also operates the First and Second Affiliated General Hospitals, as well as the Stomatological Hospital.
Chairman and CEO of BSPM, Ronghua Wang, telegraphed shareholder excitement about the Company being selected as one of only nine Chinese pharma companies for such a prestigious cooperation agreement with the FMMU; noting Biostar’s lean architecture and vertically integrated business model, deep R&D competencies, manufacturing and marketing prowess. Wang reaffirmed the Company’s commitment to increasing shareholder value through expanded product range, improved sales volume and overall efficiency/profitability through periods of sustained growth.
The audience of some 3k doctors, professors and professional members of the Chinese medical community, including executives from over 500 pharma companies, listened intently as Wang detailed projected collaboration between BSPM and the FMMU in advancing the products covered under the agreement through Phase IV clinical trials. Wang also indicated that prescribed military guidelines would entail R&D for select products intended for use solely by the PRC and the FMMU’s three hospitals. The Zushima pain suppressant spray BSPM developed for the military is a good example of the approach as well as the results that will be employed moving forward.
Wang went on to extol the Company’s years of dedicated effort by BSPM personnel in nurturing strategic relationships with key universities throughout China, like the Shaanxi College of Traditional Chinese Medicine and Shaanxi University of Science and Technology, as well as the Northwest University College of Life Science. This diligent effort, in conjunction with the newly acquired FMMU cooperation, has positioned BSPM for unprecedented growth on the surging projections in the pharma sector.
Huge news for BSPM, being selected out of so many candidates in the FMMU’s rigorous screening process, and it all came down to the incredibly positive track record set by the Company in everything from R&D milestones to clinical trial completion and product efficacy.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Two Sided Growth Strategy of AdCare Health Systems, Inc. (ADK)
It’s AdCare’s spectacular revenue growth over the past few years, roughly doubling every year since 2009, that has caught the eye of investors, with much of the attention going to the company’s increasing number of acquisitions. AdCare, a healthcare services provider that owns and operates a growing number of skilled nursing homes, assisted living facilities, and other care facilities, has a strategy designed to take advantage of a fragmented industry that is weighted toward long-term low margin care. The company has been able to acquire these small privately-owned operations, and transform them to higher-margin short term care facilities for which there is an increasing demand-supply gap. These short-term facilities support patients recovering from strokes or other health crises, and can often tap into Medicare.
The acquisition side of the equation has promoted dramatic revenue growth, but equally important is the second key aspect to AdCare’s strategy. In addition to growing through acquisitions, the company has also been growing Medicare support and reimbursement rates at the acquired facilities by increasing facility acuity level. Emphasizing shorter term higher intensity care improves margins and per-facility revenue. The company also has a track record of improving margins at facilities through instituting a number of other operational efficiencies.
Profitably moving a care facility from a long-term care model to an optimized higher-acuity model is not a simple process. It requires ensuring the ability to adhere to the necessary government requirements, and also requires a strong familiarity with associated reimbursement policies and economic environment within each state. AdCare has gone to great lengths to avoid expanding into states that are experiencing significant economic problems.
The optimization process also takes time. It can take a year to realize the full potential of a given facility, but that also means that AdCare’s current portfolio represents considerable opportunity for financial growth over and above upcoming acquisitions.
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The acquisition side of the equation has promoted dramatic revenue growth, but equally important is the second key aspect to AdCare’s strategy. In addition to growing through acquisitions, the company has also been growing Medicare support and reimbursement rates at the acquired facilities by increasing facility acuity level. Emphasizing shorter term higher intensity care improves margins and per-facility revenue. The company also has a track record of improving margins at facilities through instituting a number of other operational efficiencies.
Profitably moving a care facility from a long-term care model to an optimized higher-acuity model is not a simple process. It requires ensuring the ability to adhere to the necessary government requirements, and also requires a strong familiarity with associated reimbursement policies and economic environment within each state. AdCare has gone to great lengths to avoid expanding into states that are experiencing significant economic problems.
The optimization process also takes time. It can take a year to realize the full potential of a given facility, but that also means that AdCare’s current portfolio represents considerable opportunity for financial growth over and above upcoming acquisitions.
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
rVue Holdings, Inc. (RVUE) is “One to Watch”
As digital technology continues to develop a dominating role in modern society, its growing application to advertising and mass communication has been ongoing and inevitable. Perhaps the best example is the spread of digital out-of-home, which includes digital signage and other advanced electronic displays. Today, it’s one of the fastest growing media, simply because it has so many advantages over traditional forms of display. It can better engage the viewer with changing and moving images. It’s easy and quick to modify or switch out even a large number of displays. And, perhaps most important, it can be set up to target presentations to specific audiences, zeroing in on demographics or virtually any parameter for which there is meaningful data. Add in the possibility of viewer interactivity, and the quantum leap in communication becomes obvious.
The problem rests not in the lack of digital networks, or vendors anxious to use them, but rather in the overwhelming and largely disorganized volume of opportunities on both sides. Owners of individual networks of displays somehow have to identify and reach the local, regional, or national vendors that would be interested in getting their message out to those viewers. Individual vendors have to wade through the constantly growing and changing universe of networks to find the mix of displays that works best for them.
Enter rVue Holdings, a Florida based company that has, in their own words, “developed the only gateway for buyers and sellers to transact in a digital marketplace.” For advertisers, rVue offers the most comprehensive one-stop solution for the planning and buying of digital out-of-home media. Their Demand-Side Platform simplifies the planning, buying, and implementation of digital campaigns, offering up hundreds of millions of daily impressions, representing over 160 U.S. and Canadian networks, covering a range of demographic profiles. For network owners and operators, rVue is a no-subscription, no enrollment fee way to reach a world of interested vendors.
The bottom line is that rVue Holdings represents a unique service offering to a market that continues to experience double digit growth. Not a bad combination.
For additional information, visit the company’s website at www.rVue.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The problem rests not in the lack of digital networks, or vendors anxious to use them, but rather in the overwhelming and largely disorganized volume of opportunities on both sides. Owners of individual networks of displays somehow have to identify and reach the local, regional, or national vendors that would be interested in getting their message out to those viewers. Individual vendors have to wade through the constantly growing and changing universe of networks to find the mix of displays that works best for them.
Enter rVue Holdings, a Florida based company that has, in their own words, “developed the only gateway for buyers and sellers to transact in a digital marketplace.” For advertisers, rVue offers the most comprehensive one-stop solution for the planning and buying of digital out-of-home media. Their Demand-Side Platform simplifies the planning, buying, and implementation of digital campaigns, offering up hundreds of millions of daily impressions, representing over 160 U.S. and Canadian networks, covering a range of demographic profiles. For network owners and operators, rVue is a no-subscription, no enrollment fee way to reach a world of interested vendors.
The bottom line is that rVue Holdings represents a unique service offering to a market that continues to experience double digit growth. Not a bad combination.
For additional information, visit the company’s website at www.rVue.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Nexxus Lighting, Inc. (NEXS) Announces Full ENERGY STAR® Qualification for Two Array LED Light Bulbs
Nexxus Lighting Inc., a leader in high performance LED replacement light bulbs with its Array® Lighting line of products, today announced that the Array R30 3000K Flood and the 3000K Accent LED light bulbs can now be marketed with a life certification of 50,000 hours after receiving full ENERGY STAR qualification. In October of 2010, the bulbs earned the ENERGY STAR mark and now the final round of lumen maintenance testing demonstrates that each bulb will last the equivalent of 10 years when the lamp is on for twelve hours per day.
“All of the Array LED bulbs are designed to exceed ENERGY STAR performance criteria, and we are proud to say that Nexxus is the first manufacturer on the ENERGY STAR Qualified Lamps list to have LED reflector lamp replacements with a life claim of 50,000 hours,” stated Mike Bauer, President and CEO of Nexxus Lighting, Inc. in a press release. “We currently have several more Array bulbs in testing for the ENERGY STAR label, and we will continue to bring best in class, high performance LED replacement lamps to market.”
The Array Lighting line of products, including the R30s, is one of the first LED reflector lamp replacements to earn the full 50,000 hour certification. The bulbs were put through 12,500 hours of third party lumen maintenance testing and had to meet all EPA standards for lumen and color maintenance, efficiency, color rendering and more.
In the beginning of this month, a new Federal law went into effect that phases out the traditional standard 100-watt incandescent light bulbs. The majority of new bulbs will operate and look like the old-fashioned bulbs but they will have improved filament design which will make them 28% more efficient per the new law. Additionally, all new bulbs will be labeled with lumens instead of watts to describe the amount of light emitted versus amount of power used. Instead of a 100 watt bulb, customers will seek a 1600 lumens bulb. The increased initial cost will actually turn into a savings over the life of each bulb.
Nexxus Lighting holds 39 US and foreign patents on its Array Lighting products and has 32 patents pending. The LED bulbs use a unique approach to thermal management to ensure over 50,000 hours of reliable operation. Further, the Array bulbs decrease energy consumption up to 80% over the traditional incandescent and halogen bulbs.
For more information, please visit www.nexxuslighting.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“All of the Array LED bulbs are designed to exceed ENERGY STAR performance criteria, and we are proud to say that Nexxus is the first manufacturer on the ENERGY STAR Qualified Lamps list to have LED reflector lamp replacements with a life claim of 50,000 hours,” stated Mike Bauer, President and CEO of Nexxus Lighting, Inc. in a press release. “We currently have several more Array bulbs in testing for the ENERGY STAR label, and we will continue to bring best in class, high performance LED replacement lamps to market.”
The Array Lighting line of products, including the R30s, is one of the first LED reflector lamp replacements to earn the full 50,000 hour certification. The bulbs were put through 12,500 hours of third party lumen maintenance testing and had to meet all EPA standards for lumen and color maintenance, efficiency, color rendering and more.
In the beginning of this month, a new Federal law went into effect that phases out the traditional standard 100-watt incandescent light bulbs. The majority of new bulbs will operate and look like the old-fashioned bulbs but they will have improved filament design which will make them 28% more efficient per the new law. Additionally, all new bulbs will be labeled with lumens instead of watts to describe the amount of light emitted versus amount of power used. Instead of a 100 watt bulb, customers will seek a 1600 lumens bulb. The increased initial cost will actually turn into a savings over the life of each bulb.
Nexxus Lighting holds 39 US and foreign patents on its Array Lighting products and has 32 patents pending. The LED bulbs use a unique approach to thermal management to ensure over 50,000 hours of reliable operation. Further, the Array bulbs decrease energy consumption up to 80% over the traditional incandescent and halogen bulbs.
For more information, please visit www.nexxuslighting.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, January 20, 2012
FieldPoint Petroleum Corp. (FPP) Provides Update on Production at New Mexico Field
FieldPoint Petroleum recently reported an update on the company’s oil and gas activities in New Mexico.
FieldPoint Petroleum is involved with Cimarex Energy (XEC) on the East Lusk Federal 15 well #1 in Lea County, New Mexico. The well targeted the Bone Spring formation and was completed in December 2011 with initial production of 446 barrels of oil per day.
FieldPoint Petroleum reported that the well produced 735 barrels of oil and 588,000 cubic feet of natural gas per day on January 17, 2012. The most recent production report from the operator of the well has production at 673 barrels of oil and 624,000 cubic feet of natural gas per day. The company said that the extra production relative to the initially reported rate was due to a larger choke size used during operations.
FieldPoint Petroleum owns a 43.75% working interest in the well, and based on the agreement with the operator, will own a similar working interest in future wells on the property. The company anticipates a second well will be drilled on the East Lusk Federal 15 property in 2012.
For more information on the company, go to www.fppcorp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
FieldPoint Petroleum is involved with Cimarex Energy (XEC) on the East Lusk Federal 15 well #1 in Lea County, New Mexico. The well targeted the Bone Spring formation and was completed in December 2011 with initial production of 446 barrels of oil per day.
FieldPoint Petroleum reported that the well produced 735 barrels of oil and 588,000 cubic feet of natural gas per day on January 17, 2012. The most recent production report from the operator of the well has production at 673 barrels of oil and 624,000 cubic feet of natural gas per day. The company said that the extra production relative to the initially reported rate was due to a larger choke size used during operations.
FieldPoint Petroleum owns a 43.75% working interest in the well, and based on the agreement with the operator, will own a similar working interest in future wells on the property. The company anticipates a second well will be drilled on the East Lusk Federal 15 property in 2012.
For more information on the company, go to www.fppcorp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Spine Pain Management, Inc. (SPIN) is “One to Watch”
It’s well known that one of the biggest headaches doctors and healthcare givers have is dealing with the variety of patient healthcare plans in order to maintain a timely and healthy cash flow. Cash flows for doctors have been significantly affected by government programs and insurance companies, forcing many providers into a cash flow crisis. It’s a problem that has compromised not only the financial health of providers, but also the quality of medical care they provide. The result has been a clear and growing need for a system that removes much of the cash flow burden and risk from doctors, replacing it with predictable income for doctors and an efficient support program for patients that ensures the best results for everyone involved. It’s a gap being filled successfully by Texas-based Spine Pain Management.
From the medical provider’s perspective, Spine Pain Management is a medical, management, billing, and collection service, that functions essentially as a medical receivables purchase company. Doctors in affiliated centers contract with SPIN to shift financial risk in the collection of accounts receivables. SPIN pays these providers a percentage of the gross billing up-front, upon completion of each covered medical procedure, giving them immediate and predictable cash flow. SPIN thus assumes the risk and time involved in final collection.
For patients involved in work related injuries or other accidents, SPIN represents a managed support and advocacy program to assist injured patients in receiving the appropriate treatment needed to maximize outcome. SPIN coordinates financial programs with the patient’s doctor, facilitating the selection of optimum diagnostic and treatment procedures.
The focus of Spine Pain Management is, as the name implies, the patient who has sustained traumatic spine injuries, delivering turnkey solutions to spinal health care providers for the necessary treatment of musculo-skeletal injuries resulting from accidents. Promoting early treatment reduces the chance that injuries will escalate.
In the U.S. alone, spine treatment represents an expanding multi-billion dollar market, with rapid growth expected to continue for the foreseeable future. SPIN plans to continue rolling out its well-received business model across the U.S. into major metropolitan cities through affiliates comprised of established spine clinics.
For additional information, visit the company’s website at www.SpinePainInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
From the medical provider’s perspective, Spine Pain Management is a medical, management, billing, and collection service, that functions essentially as a medical receivables purchase company. Doctors in affiliated centers contract with SPIN to shift financial risk in the collection of accounts receivables. SPIN pays these providers a percentage of the gross billing up-front, upon completion of each covered medical procedure, giving them immediate and predictable cash flow. SPIN thus assumes the risk and time involved in final collection.
For patients involved in work related injuries or other accidents, SPIN represents a managed support and advocacy program to assist injured patients in receiving the appropriate treatment needed to maximize outcome. SPIN coordinates financial programs with the patient’s doctor, facilitating the selection of optimum diagnostic and treatment procedures.
The focus of Spine Pain Management is, as the name implies, the patient who has sustained traumatic spine injuries, delivering turnkey solutions to spinal health care providers for the necessary treatment of musculo-skeletal injuries resulting from accidents. Promoting early treatment reduces the chance that injuries will escalate.
In the U.S. alone, spine treatment represents an expanding multi-billion dollar market, with rapid growth expected to continue for the foreseeable future. SPIN plans to continue rolling out its well-received business model across the U.S. into major metropolitan cities through affiliates comprised of established spine clinics.
For additional information, visit the company’s website at www.SpinePainInc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
US Gold Corp. (UXG) and Minera Andes (MAI.TO) Get Stockholder Approval to Merge
US Gold Corp. is a gold and silver exploration company with an emphasis on the Americas. The company is advancing its El Gallo silver and gold project in Mexico, and its Gold bar gold project in Nevada. It has a strong treasury with about $100 million cash along with gold and silver bullion.
Both US Gold and Minera Andes announced today that at each of their respective shareholders meetings on January 19, 2012, stockholders voted in favor of the proposed merger of the two companies. Minera Andes is an explorer of gold, silver and copper in Argentina.
Under the previously announced terms of the deal, Minera Andes’ shareholders will receive 0.45 share of the new company for each share they hold. The newly merged company will change its name to McEwen Mining Inc. The company is being named after the founder, CEO and largest shareholder (20%) of US Gold, Robert McEwen.
His goal has been to grow the company both organically and through acquisitions to become large enough for inclusion in the S&P 500 stock index. After approval of the deal, Mr. McEwen said, “This brings us one step closer to qualifying for the S&P 500. We look forward to future growth and prosperity this combination creates.”
For additional information about the two mining companies, please visit both www.usgold.com and www.minandes.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Both US Gold and Minera Andes announced today that at each of their respective shareholders meetings on January 19, 2012, stockholders voted in favor of the proposed merger of the two companies. Minera Andes is an explorer of gold, silver and copper in Argentina.
Under the previously announced terms of the deal, Minera Andes’ shareholders will receive 0.45 share of the new company for each share they hold. The newly merged company will change its name to McEwen Mining Inc. The company is being named after the founder, CEO and largest shareholder (20%) of US Gold, Robert McEwen.
His goal has been to grow the company both organically and through acquisitions to become large enough for inclusion in the S&P 500 stock index. After approval of the deal, Mr. McEwen said, “This brings us one step closer to qualifying for the S&P 500. We look forward to future growth and prosperity this combination creates.”
For additional information about the two mining companies, please visit both www.usgold.com and www.minandes.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
What Medical Imaging Can Do for You
It’s almost impossible to overstate the significance of medical imaging in the development of modern medicine. The New England Journal of Medicine, considered the world’s oldest and single most influential general medical periodical, calls medical imaging one of the top medical developments of the last millennium. You might say that imaging is to medicine what the telescope is to astronomy. Modern medicine would simply not exist without it.
Basically, medical imaging gives health professionals views of the human body, inside and out, to reveal exactly what’s working and what’s not in ways previously not possible. In so doing, it has guided doctors in the saving of countless lives, and has created a multi-billion dollar global industry. It’s an industry that continues to grow, as even small providers realize that they can now purchase used equipment, such as an MRI machine, and realize a hefty return on their investment in a relatively short time, turning a few hundred thousand dollars into millions. Today, the sheer volume of medical imaging has come under fire as feeding the rising costs of health care, a claim hotly contested by the industry.
From its beginnings in 1895, with the discovery of the X-ray, medical imaging has branched out to encompass a range of technologies for uncovering the structure and processes within the human body. Each technology has its own strengths and weaknesses, and is used for identifying specific types of internal problems. Below is a breakdown of the principal imaging technologies used today and what they offer, along with examples of successful publicly traded companies directly associated with them.
• X-Ray – The grandfather of medical imaging, X-rays are still the most frequently used imaging technology. X-ray imaging, a form of highly penetrative electromagnetic radiation, is used for viewing broken bones, but also for dense tumors, as in breast cancer, for lung evaluation, and for spotting foreign objects, such as bullets or swallowed items. Of course it’s also used in dentistry, as well as for non-medical applications, such as security checks at airports.
The best known player in X-rays, and the biggest player in all medical imaging, is General Electric (NYSE: GE), but the company is facing controversy for their earlier announcement of a planned move of its X-ray operations from Wisconsin to China. Varian Medical Systems (NYSE: VAR), based in California, offers hundreds of medical and industrial X-ray tubes, and has a consistent record of growing sales and earnings.
• Computed Tomography (CT) – Usually called CAT scan, CT uses computer processing to combine multiple X-ray images, creating image cross-section slices of a 3D form. It involves more radiation than a standard X-ray, but is good for imaging tumors and various body organs, including the colon, as well as blockages of lung arteries, and for evaluating such things as possible appendicitis. CT scanning has also proven to be an important tool in the war against lung cancer.
Toshiba (OTN: TOSBF), a major producer of imaging and other equipment, is the maker of the award winning Aquilion ONE CT Scanner.
• Magnetic Resonance Imaging (MRI) – MRI uses a strong magnetic field to align various atoms in the body, and then manipulates them with radio waves to generate magnetic signals that can be detected and processed, creating an image. MRI is especially useful for imaging soft tissues, such as breast, heart, and liver, where it is sensitive enough to differentiate diseased tissue from healthy tissue, as well as for fractures, tumors, and arthritis.
Netherlands based Royal Philips Electronics (NYSE: PHG) is a world leader in healthcare related technologies and equipment, producing a wide range of MRI systems.
• Ultrasound – Considered the least invasive in terms of radiation, ultrasound (sometimes called ultrasonography) uses high-frequency sound waves to generate pictures of soft tissues, including real-time moving images, often related to pregnancy or various organs, such as the heart and blood vessels.
Samsung Electronics (OTN: SSNLF), aiming to expand its healthcare market competition with Philips and GE, recently entered the ultrasound market by purchasing a majority stake in South Korean ultrasound manufacturer Medison.
• Positron Emission Tomography (PET) – Unique in its ability to get down to cellular processes, PET, a cutting-edge, rapidly growing branch of nuclear medicine, uses short-lived radioactive chemicals that can, depending upon the chemicals used, provide vital information regarding neurological diseases, heart disease, and cancer. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified.
FluoroPharma Medical (OTCBB: FPMI) does not focus on PET equipment, but rather the critically important imaging agents, the chemicals that allow PET technology to see the cellular processes associated with heart disease and other major diseases. Clinical trials have already confirmed FluoroPharma’s imaging agents are safe and are now establishing their efficacy.
The company’s broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. FluoroPharma has four issued U.S. patents, with seven pending applications, together with strong international protection. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Basically, medical imaging gives health professionals views of the human body, inside and out, to reveal exactly what’s working and what’s not in ways previously not possible. In so doing, it has guided doctors in the saving of countless lives, and has created a multi-billion dollar global industry. It’s an industry that continues to grow, as even small providers realize that they can now purchase used equipment, such as an MRI machine, and realize a hefty return on their investment in a relatively short time, turning a few hundred thousand dollars into millions. Today, the sheer volume of medical imaging has come under fire as feeding the rising costs of health care, a claim hotly contested by the industry.
From its beginnings in 1895, with the discovery of the X-ray, medical imaging has branched out to encompass a range of technologies for uncovering the structure and processes within the human body. Each technology has its own strengths and weaknesses, and is used for identifying specific types of internal problems. Below is a breakdown of the principal imaging technologies used today and what they offer, along with examples of successful publicly traded companies directly associated with them.
• X-Ray – The grandfather of medical imaging, X-rays are still the most frequently used imaging technology. X-ray imaging, a form of highly penetrative electromagnetic radiation, is used for viewing broken bones, but also for dense tumors, as in breast cancer, for lung evaluation, and for spotting foreign objects, such as bullets or swallowed items. Of course it’s also used in dentistry, as well as for non-medical applications, such as security checks at airports.
The best known player in X-rays, and the biggest player in all medical imaging, is General Electric (NYSE: GE), but the company is facing controversy for their earlier announcement of a planned move of its X-ray operations from Wisconsin to China. Varian Medical Systems (NYSE: VAR), based in California, offers hundreds of medical and industrial X-ray tubes, and has a consistent record of growing sales and earnings.
• Computed Tomography (CT) – Usually called CAT scan, CT uses computer processing to combine multiple X-ray images, creating image cross-section slices of a 3D form. It involves more radiation than a standard X-ray, but is good for imaging tumors and various body organs, including the colon, as well as blockages of lung arteries, and for evaluating such things as possible appendicitis. CT scanning has also proven to be an important tool in the war against lung cancer.
Toshiba (OTN: TOSBF), a major producer of imaging and other equipment, is the maker of the award winning Aquilion ONE CT Scanner.
• Magnetic Resonance Imaging (MRI) – MRI uses a strong magnetic field to align various atoms in the body, and then manipulates them with radio waves to generate magnetic signals that can be detected and processed, creating an image. MRI is especially useful for imaging soft tissues, such as breast, heart, and liver, where it is sensitive enough to differentiate diseased tissue from healthy tissue, as well as for fractures, tumors, and arthritis.
Netherlands based Royal Philips Electronics (NYSE: PHG) is a world leader in healthcare related technologies and equipment, producing a wide range of MRI systems.
• Ultrasound – Considered the least invasive in terms of radiation, ultrasound (sometimes called ultrasonography) uses high-frequency sound waves to generate pictures of soft tissues, including real-time moving images, often related to pregnancy or various organs, such as the heart and blood vessels.
Samsung Electronics (OTN: SSNLF), aiming to expand its healthcare market competition with Philips and GE, recently entered the ultrasound market by purchasing a majority stake in South Korean ultrasound manufacturer Medison.
• Positron Emission Tomography (PET) – Unique in its ability to get down to cellular processes, PET, a cutting-edge, rapidly growing branch of nuclear medicine, uses short-lived radioactive chemicals that can, depending upon the chemicals used, provide vital information regarding neurological diseases, heart disease, and cancer. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified.
FluoroPharma Medical (OTCBB: FPMI) does not focus on PET equipment, but rather the critically important imaging agents, the chemicals that allow PET technology to see the cellular processes associated with heart disease and other major diseases. Clinical trials have already confirmed FluoroPharma’s imaging agents are safe and are now establishing their efficacy.
The company’s broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. FluoroPharma has four issued U.S. patents, with seven pending applications, together with strong international protection. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
First Titan Corp. (FTTN) to Acquire Significant Working Interest in Oil and Gas Lease in West Texas
Located in Bradenton, Florida, First Titan Corp., through its wholly owned subsidiary First Titan Energy, LLC, is a rising company that is committed to the exploration and development of oil and natural gas resources across the world. Today, FTTN announced they have entered into negotiations to acquire a significant working interest in an oil and gas lease in West Texas.
FTTN is targeting the Big Canyon Prospect in Terrell County, Texas. The young company is wrapping up due diligence on the lease and expects to sign a purchase agreement with the prospective seller early next week.
Last week FTTN announced the acquisition of a working interest in a new well to be drilled in South Lake Charles, La. If negotiations are successful, the Big Canyon Prospect will be the second oil and gas lease in which FTTN will own a working interest in.
FTTN is working to develop new energy solutions to compete in this booming industry. With this deal in place, FTTN is on the radar with such companies as: Chesapeake Energy Corp. (NYSE: CHK), Anadarko Petroleum Corp. (NYSE: APC), Apache Corp. (NYSE: APA) and SandRidge Energy Inc. (NYSE: SD).
Currently, FTTN is trading in the $2.15 range. To learn more about the company as a whole, visit their corporate website at www.firsttitanenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
FTTN is targeting the Big Canyon Prospect in Terrell County, Texas. The young company is wrapping up due diligence on the lease and expects to sign a purchase agreement with the prospective seller early next week.
Last week FTTN announced the acquisition of a working interest in a new well to be drilled in South Lake Charles, La. If negotiations are successful, the Big Canyon Prospect will be the second oil and gas lease in which FTTN will own a working interest in.
FTTN is working to develop new energy solutions to compete in this booming industry. With this deal in place, FTTN is on the radar with such companies as: Chesapeake Energy Corp. (NYSE: CHK), Anadarko Petroleum Corp. (NYSE: APC), Apache Corp. (NYSE: APA) and SandRidge Energy Inc. (NYSE: SD).
Currently, FTTN is trading in the $2.15 range. To learn more about the company as a whole, visit their corporate website at www.firsttitanenergy.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, January 19, 2012
Overland Storage, Inc. (OVRL) Signs Strategic Reseller Agreement with Zycko to Increase Sales within SME Sector in Northern Europe
Overland Storage, a global provider of data management and data protection solutions across the data lifecycle, today announced a new agreement with Zycko, an international value-added distributor of leading edge IT solutions, to expand the northern European distribution channel for its award winning storage solutions. This strategic agreement will utilize Zycko’s expert resellers, systems integrator and service providers to bring storage solutions like the recently launched SnapServer DX series to Zycko’s clients in the SME sector.
“We are delighted to be able to provide Overland Storage solutions to our clients, we see this as an excellent opportunity to establish new partners within the SME sector. Many of our existing EMEA partners have been asking for cost effective storage solutions to complement many of the enterprise solutions we already offer. For example the SnapServer DX Series gives Zycko a credible and flexible NAS solution for partners, but without compromising performance or reliability,” said Darren Sheppard, manager of vendor solutions division, Zycko in a press statement.
The SnapServer DX protects a company’s data and lets storage grow seamlessly without need for IT intervention. This product is geared towards small businesses with growing storage needs that desire to protect and share data with easy expansion and management. The SnapServer works across Widows UNIX/Linux and Macintosh Platforms allowing the sharing of data. Data can be replicated between a central location and one or more remote locations and can be protected with snapshots or replication.
“One of Zycko’s biggest strengths is the range of professional services they offer to each individual customer, including full technical, marketing and business development support.” said Andy Walsky, VP EMEA sales, Overland Storage in a press statement. “Expanding our presence in the SME market is key to our business development strategy. We are confident that Zycko’s technical competence and deep understanding and knowledge of its customers in this marketplace will enable us to accomplish this.”
Zycko started providing customers with OEM accessories for the networking channel back in 1999. As it grew, the company began working with leading-edge strategic partners and technologies to provide customers with services for networking, virtualization, data storage and data centers. Over the years Zycko has grown overseas with offices in 13 countries, including its headquarters in the UK. They also offer clients accredited training, marketing and business development support.
For more information on Overland Storage, please visit www.overlandstorage.com
For information on Zycko, please visit www.zycko.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We are delighted to be able to provide Overland Storage solutions to our clients, we see this as an excellent opportunity to establish new partners within the SME sector. Many of our existing EMEA partners have been asking for cost effective storage solutions to complement many of the enterprise solutions we already offer. For example the SnapServer DX Series gives Zycko a credible and flexible NAS solution for partners, but without compromising performance or reliability,” said Darren Sheppard, manager of vendor solutions division, Zycko in a press statement.
The SnapServer DX protects a company’s data and lets storage grow seamlessly without need for IT intervention. This product is geared towards small businesses with growing storage needs that desire to protect and share data with easy expansion and management. The SnapServer works across Widows UNIX/Linux and Macintosh Platforms allowing the sharing of data. Data can be replicated between a central location and one or more remote locations and can be protected with snapshots or replication.
“One of Zycko’s biggest strengths is the range of professional services they offer to each individual customer, including full technical, marketing and business development support.” said Andy Walsky, VP EMEA sales, Overland Storage in a press statement. “Expanding our presence in the SME market is key to our business development strategy. We are confident that Zycko’s technical competence and deep understanding and knowledge of its customers in this marketplace will enable us to accomplish this.”
Zycko started providing customers with OEM accessories for the networking channel back in 1999. As it grew, the company began working with leading-edge strategic partners and technologies to provide customers with services for networking, virtualization, data storage and data centers. Over the years Zycko has grown overseas with offices in 13 countries, including its headquarters in the UK. They also offer clients accredited training, marketing and business development support.
For more information on Overland Storage, please visit www.overlandstorage.com
For information on Zycko, please visit www.zycko.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
National Technical Systems (NTSC) Inks Agreement with RF Exposure Lab to Expand Wireless Solutions and Services
National Technical Systems Inc. (“NTS”), a leading provider of testing and engineering services for the aerospace, defense and other high-technology markets, today announced it has signed an exclusive business alliance with RF Exposure Lab LLC to provide radio frequency (RF) safety testing services at NTS’ Silicon Valley test laboratories.
These services are offered only by certified wireless labs and represent a key component to NTS’ wireless solutions portfolio. NTS said that by adding these services, the company can offer a single-source testing and certification solution for wireless device manufacturers around the world.
“The addition of these new RF safety services combined with our existing wireless testing and certifications portfolio and our in-house FCC Telecommunications Certification Body makes NTS the obvious go-to choice for wireless device manufacturers both large and small,” William McGinnis, president and CEO of NTS stated in the press release. “Adding these RF services is yet another step forward in our strategy to diversify our capabilities in line with the demand from our customers, in this case the rapidly-expanding wireless services market.”
RF is a leading provider of Specific Absorption Rate (SAR) testing and certification services, which are required by the Federal Communications Commission for many types of hand-held wireless devices such as cellphones and PDAs sold in the United States. On a global scale, there are also similar regulatory requirements for these devices in most major foreign markets.
Per the agreement, RF will provide the test equipment and technical training required for NTS to provide SAR testing and certification services to its global customer base. Upon full installation, NTS estimates that annual service fees could reach as high as $1 million, which will be split equally between NTS and RF.
For more information visit www.nts.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
These services are offered only by certified wireless labs and represent a key component to NTS’ wireless solutions portfolio. NTS said that by adding these services, the company can offer a single-source testing and certification solution for wireless device manufacturers around the world.
“The addition of these new RF safety services combined with our existing wireless testing and certifications portfolio and our in-house FCC Telecommunications Certification Body makes NTS the obvious go-to choice for wireless device manufacturers both large and small,” William McGinnis, president and CEO of NTS stated in the press release. “Adding these RF services is yet another step forward in our strategy to diversify our capabilities in line with the demand from our customers, in this case the rapidly-expanding wireless services market.”
RF is a leading provider of Specific Absorption Rate (SAR) testing and certification services, which are required by the Federal Communications Commission for many types of hand-held wireless devices such as cellphones and PDAs sold in the United States. On a global scale, there are also similar regulatory requirements for these devices in most major foreign markets.
Per the agreement, RF will provide the test equipment and technical training required for NTS to provide SAR testing and certification services to its global customer base. Upon full installation, NTS estimates that annual service fees could reach as high as $1 million, which will be split equally between NTS and RF.
For more information visit www.nts.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
VistaGen Therapeutics (VSTA) Validates Key Heart Toxicity Bioassay System
According to Dr. Ralph Snodgrass, President and Chief Scientific Officer and co-founder of VistaGen, a biotechnology company applying stem cell technology for drug rescue, cardiotoxicity (heart toxicity) has been implicated in almost 30% of drug withdrawals in the United States over the last 30 years.
Such late-stage withdrawals represent a huge loss for the pharmaceutical industry, and pose significant risks to early users of such drugs. Unfortunately, current drug testing methods have important limitations in their ability to predict cardiotoxicity in human users. Traditional evaluation methods depend upon animal testing, although animals respond differently than humans to many drugs, or on cell lines that are engineered, transformed, non-human, and/or of non-cardiac lineage, or focused on effects relating to a single cardiac ion channel. Such methods yield both false positive and false negative results. What is needed is an accurate early-stage identification of potential cardiotoxicity, one of the key stem cell technology applications which VistaGen’s Human Clinical Trials in a Test Tube™ platform now offers.
Through the use of advanced stem cell technology, VistaGen has produced functional human heart cells that express ion channels and auxiliary proteins relevant to the accurate evaluation of cardiac effects of new drug candidates. Most recently, VistaGen has made major progress in the validation of its human stem cell-derived “Micro-Heart” cardiotoxicity bioassay system, CardioSafe 3D™.
The system was validated by measuring the dose-dependent effects on cardiomyocyte cell viability and electrophysiological responses, as measured by patch clamp and field potential assays, of twelve compounds with known cardiac cytotoxicity or electrophysiology effects. Tests showed that the system is highly reproducible, and has a strong concordance with the in-vivo cardiac effects of multiple classes of compounds.
VistaGen has developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed cells, which can be used to create novel bioassay systems for predictive toxicology, drug discovery, drug rescue, and cell therapy applications.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Such late-stage withdrawals represent a huge loss for the pharmaceutical industry, and pose significant risks to early users of such drugs. Unfortunately, current drug testing methods have important limitations in their ability to predict cardiotoxicity in human users. Traditional evaluation methods depend upon animal testing, although animals respond differently than humans to many drugs, or on cell lines that are engineered, transformed, non-human, and/or of non-cardiac lineage, or focused on effects relating to a single cardiac ion channel. Such methods yield both false positive and false negative results. What is needed is an accurate early-stage identification of potential cardiotoxicity, one of the key stem cell technology applications which VistaGen’s Human Clinical Trials in a Test Tube™ platform now offers.
Through the use of advanced stem cell technology, VistaGen has produced functional human heart cells that express ion channels and auxiliary proteins relevant to the accurate evaluation of cardiac effects of new drug candidates. Most recently, VistaGen has made major progress in the validation of its human stem cell-derived “Micro-Heart” cardiotoxicity bioassay system, CardioSafe 3D™.
The system was validated by measuring the dose-dependent effects on cardiomyocyte cell viability and electrophysiological responses, as measured by patch clamp and field potential assays, of twelve compounds with known cardiac cytotoxicity or electrophysiology effects. Tests showed that the system is highly reproducible, and has a strong concordance with the in-vivo cardiac effects of multiple classes of compounds.
VistaGen has developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed cells, which can be used to create novel bioassay systems for predictive toxicology, drug discovery, drug rescue, and cell therapy applications.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, January 18, 2012
AdCare Health Systems, Inc. (ADK) Displays Unique and Successful Growth Strategy
When Stonegate Securities came out with their positive report on AdCare Health Systems, a rapidly expanding provider of nursing homes and care facilities, they focused on how the new management team has helped transition the company to a superior growth strategy, a strategy giving AdCare significantly better growth rates than the industry average.
The report gives spectacular projected growth rates for AdCare over the next few years, and then goes on to say that the given figures also have notable upside potential, since they do not include currently unannounced acquisitions in the pipeline. Considering that the anticipated ADK growth figure given for 2012 is 87%, versus a 6% average for the industry, it clearly sets AdCare apart. The report concludes conservatively that ADK is creating incremental and sustainable value for its shareholders.
The current state of the care facility industry is one of fragmentation, with the majority of facilities being small, privately owned, individually managed, long-term and tight-margin operations. Short-term care facilities, for people recovering from strokes, heart attacks, or other health crisis, often covered by Medicare, offer a significantly higher margin, but fewer such facilities are being built. The AdCare approach, unique in the industry, is to acquire the low-end operations and move them to the higher-end model, using proven management techniques to increase efficiency while actually improving the care provided. It is a challenge, requiring working closely with state regulators, but AdCare has identified the best states for what they are doing.
AdCare prefers to own versus lease, but evaluates each acquisition opportunity on its own mix of merits. The company has already grown dramatically, now with dozens of facilities spread over Ohio, Georgia, Arkansas, Alabama, and North Carolina, with new ones always on the way,
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The report gives spectacular projected growth rates for AdCare over the next few years, and then goes on to say that the given figures also have notable upside potential, since they do not include currently unannounced acquisitions in the pipeline. Considering that the anticipated ADK growth figure given for 2012 is 87%, versus a 6% average for the industry, it clearly sets AdCare apart. The report concludes conservatively that ADK is creating incremental and sustainable value for its shareholders.
The current state of the care facility industry is one of fragmentation, with the majority of facilities being small, privately owned, individually managed, long-term and tight-margin operations. Short-term care facilities, for people recovering from strokes, heart attacks, or other health crisis, often covered by Medicare, offer a significantly higher margin, but fewer such facilities are being built. The AdCare approach, unique in the industry, is to acquire the low-end operations and move them to the higher-end model, using proven management techniques to increase efficiency while actually improving the care provided. It is a challenge, requiring working closely with state regulators, but AdCare has identified the best states for what they are doing.
AdCare prefers to own versus lease, but evaluates each acquisition opportunity on its own mix of merits. The company has already grown dramatically, now with dozens of facilities spread over Ohio, Georgia, Arkansas, Alabama, and North Carolina, with new ones always on the way,
For additional information, visit the company’s website at www.AdCareHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)